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Copper transporting ATPases (Cu-ATPases) are essential for mediating copper
uptake, maintaining cellular copper levels and prevention of accumulation of toxic copper.
The most studied copper ATPases are the Menkes and Wilson proteins in eukaryotes,
CopA and CopB found in bacteria. The precise interaction of the metal binding domains
with their copper donor, the association of each metal binding domain within the Nterminal portion of the protein, how they communicate with each other, and the eventual
metal ion translocation across the membrane, is little known. The variation in number of
the cytosolic metal binding domains may also offer clues on the structural and functional
roles these Cu-ATPases play in organisms. In order to gain more insight on the structural
organizations of copper ATPases, I have studied the N-terminal domains of three copper
ATPases: (1) Wilson disease protein, (2) Dictyostelium discoideum Copper ATPases and
(3), Plasmodium falciparum copper ATPase (PfCuP-ATPase).
The N-terminal portion of Wilson protein (ATP7B) is made of six metal binding
domains which can receive copper(I) from a copper donor, HAH1, that forms a stable
adduct with metal binding domain four. I engineered a chimera of this metal binding

domain with the copper chaperone HAH1. When the chimera was denatured using
guanidine hydrochloride, it unfolded in three phases. The first and second midpoint of
unfolding is 1.37 M and 5.6 M GuHCl respectively. The midpoint of thermal unfolding is
78 ℃. The chimera was crystalized by hanging drop vapor diffusion at room temperature
using Hampton crystallization screen.
Dictyostelium discoideum has three copper ATPases: ATP1, ATP7A and ATP3.
The number and structural basis of the metal binding domains of these heavy metal
transporters is little studied. Using bioinformatics tools, circular dichroism and solution
NMR, I have identified two N-terminal domains of ATP1. Domain1 has MXCXXXC metal
binding motif that is uncommon of PIB type Cu ATPases. Copper binding studies reveal
that this domain has a high affinity for copper(I), with a KD of 2.2 * 10-18 M.
PfCuP-ATPase is a copper ATPase that is involved in copper metabolism in
Plasmodium falciparum. The number of metal-binding domains and their functions is only
partially understood. I have identified three N-terminal domains of PfCuP-ATPase and
pursued biophysical studies to better understand the structural organization of these
domains. Domain 3 is the most soluble and relatively resistant to chemical denaturation
with guanidine hydrochloride.
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N-labelled samples were prepared and 1H-15N HSQC

NMR experiments were performed for four different constructs. NMR resonance
assignments and subsequent Rosetta modelling shows domain 3 to have a ferredoxin fold
that is similar to the metal binding domains of human Wilson disease protein. Copper
binding studies were performed under anaerobic conditions with CuI(CH3CN)4+ as the
copper source, and we obtained a KD of 1.35 * 10-18 M. The presence of a two domain
construct, like that of human Wilson protein metal-binding domains five and six, yet

lacking a metal-binding motif in domain three is intriguing. This finding highlights the
structural versatility and stability of the dual ferredoxin fold.
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CHAPTER 1
COPPER METABOLISM
1.1 Introduction
A common thread running through the tapestry of aerobic life is the strict requirement for
first row transition metal ions, such as manganese, iron, cobalt, nickel, copper, and zinc.1
The chemistry catalyzed by these metals is diverse, ranging from hydrolytic chemistry all
the way to C-H activation.2 The critical nature of these metals is realized even the act of
respiration,3 wherein molecular oxygen is poised strategically between an iron and a
copper atom, prior to its stepwise reduction to water.4 Interestingly, copper is required
for high affinity iron uptake,5 in that copper enzymes modulate the oxidation of iron(II)
to iron(III),6 during its transport process – a step necessary to abrogate the formation of
rust (iron(III)oxide).7 As a side note, the most eukaryotes store iron, in the form of rust,
within the nanosized protein ferritin.8
Prior to 1995, the uptake and delivery of these first row transitions metals to their
physiological targets was poorly understood.9 One critical feature for copper is the
requirement for a pumping mechanism for mobilization within cells or for movement out
of cells.10 The concentration of ‘free copper’ within cells is quite low,11 although this
depends on the exact definition of ‘free’ and it also depends on the state of the system.
In some cases, rapid mobilization of transition metals ions occurs.12 A very good
example of the latter occurs during embryonic development, with the formation of zinc
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‘sparks’,13 as the zinc moves to the proper location of the cell. In seeds and plants,
mobilization of transition metals can be tracked via X-ray fluorescence. 14
Since copper is so vital, understanding how it is transported and delivered within cells
advances knowledge of both nutrition and disease.15 The interconnectedness living
things means that ‘simpler’ organizations affect ‘more complex’ organisms.16 In fact,
humans do not dominate the world, from a genetic diversity standpoint.17 The
requirement for copper in all organisms and the need to elucidate the cellular chemistry
of copper, has stimulated our laboratory to cross phylogenetic boundaries, broadly
speaking. The goal of this dissertation is to address key features of the chemistry of
copper that impact world health and well-being.
Copper is an essential micronutrient as it plays important catalytic and structural roles in
many enzymes. The ability of copper to cycle between oxidized and reduced states is
harnessed by Cuproenzymes. This property is required in many redox reactions.
However, the reduced copper (Cu (I)) is potentially toxic to cells since it can lead to
Fenton-like chemistry.18 The metabolism of copper in cells must therefore be tightly
controlled. Copper homeostasis involves the uptake, distribution, and secretion to meet
essential cellular requirements. It is crucial to minimize the amount of free Cu(I) in cells.
The dietary intake of copper usually exceeds tissue demands.

The homeostatic

mechanisms must therefore modulate uptake and facilitate export through the bile.
Copper uptake in cells is mediated by a copper permease protein (Ctr1).19
Intracellular copper is distributed by copper chaperones to different pathways and
organelles. This includes the copper chaperone for superoxide dismutase (CCS) that
distributes copper to superoxide dismutase (Cu/Zn SOD) in the cytosol and mitochondria,
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Antioxidant protein 1 (Atox1) may transfer copper to the nucleus20 and secretory
pathways.21 The excretion of excess copper is mediated by copper efflux ATPases,
ATP7A and ATP7B. These may also pump Cu to the Golgi apparatus. The trafficking of
copper pathways in the cell is illustrated in Figure 1. Copper is required in many enzymes
where it functions as an essential cofactor.22,23 It is also required for cellular processes
such as oxidative phosphorylation, iron metabolism, pigment formation, connective tissue
cross-linking, catecholamine synthesis, and antioxidant defense.24
Due to these distinct cellular functions, copper deficiency has profound effects that lead
to neurodegeneration and many other disability conditions.25 On the other hand, excess
copper levels have adverse effects. The impairment in biliary copper excretion results in
the liver, brain, and ocular copper overload associated with Wilson's disease.26 The redox
properties of copper may generate hydroxyl radicals through the Fenton reaction.27
Therefore, copper levels are tightly regulated to maintain sufficient supply and minimize
toxic effects.28

3

4
Figure 1.1
Copper trafficking pathways showing the movement of
copper as traced from the small intestines to various targets.

1.2 Copper import transporters and metallochaperones
1.2.1 CTR1 and CTR2
High affinity copper uptake is facilitated by a copper transport protein (Ctr1) which is
located both in the plasma membrane and the intracellular vesicles.29 Ctr1 retrieves
copper from circulation and from carrier proteins, and transports it across the basolateral
plasma membrane of the kidney, liver, placenta and mammary glands.21,30 Ctr1 makes
dietary copper available for further utilization by facilitating absorption and its release
from the vesicles.31 Copper can also enter the cells via a low affinity copper transporter,
Ctr2 that may be involved in the release of copper from the lysosomes or endocytic
vesicles.32 Ctr2 is a homolog of Ctr1 that may be involved in copper import and
intracellular homeostasis. The overexpression of Ctr2 has been associated with increased
copper uptake.

33

Ctr1 and Ctr2 donate Cu (I) to metallochaperones that distributes the

metal ion to various pathways. Copper metallochaperones are proteins that function as
intracellular Cu(I) ion shuttles, distributing Cu(I) ions to specific partner proteins, thereby
overcoming a high copper chelation capacity of the cytoplasm.24 In the cytoplasm of
many cells, metallothioneins and glutathione molecules buffer Cu(I) to deplete any free
copper ion.24
1.2.2 Atox1
Atox1 was first discovered in yeast, but also present in mammals.34 Human Atox1, also
referred to as HAH1, is a soluble protein that delivers copper to the Menkes (ATP7A)
and Wilson disease protein (ATP7B).35,36 ATP7A and ATP7B are integral membrane
proteins that transport copper in the trans-Golgi network (TGN) or across the plasma
membrane. Both ATP7A and ATP7B have six N-terminal metal binding domains that
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have similar structure to HAH1. HAH1 delivers copper to any of the six metal binding
domains. HAH1 has a !"!!"! ferredoxin fold with the metal heavy metal binding
motif, MTCXXC, located at the end of the loop of the joining the first ! sheet and "
helix (Figure 1.2).37

Figure 1.2 Crystal structure of HAH1 showing Cu(I) bound to
cysteine residues in the CXXC copper binding motif. PDB: 1FEE

One study suggests that HAH1 first delivers copper to domain two, as the first point of
entry.38 The delivery of copper from HAH1 to the metal binding domain of ATP7B may
be facilitated by protein-protein interactions for the direct transfer of copper ions.38 The
binding of copper to the metal binding domain of WDP induces conformational
rearrangements. The protein-protein interaction may be due to the variations in
electrostatic metal binding domains.39 HAH1 plays an important role in the copper
metalation pathways as well as intracellular copper efflux.34 It may also function to
6

protect neurons from oxidative stress. Overexpression of Atox1 can increase neuronal
viability under stress conditions, such as serum oxidation and deficiency.40 Cells that
lack Atox1 have impaired movement of ATP7A in response to copper levels.41
1.2.3 Cox17, Cox11 and Sco1
Cox17 and Cox11 are mitochondrial metallochaperones that deliver copper to
cytochrome c oxidase. Unlike Atox1 which delivers copper directly to the target protein,
Cox17 donates Cu(I) to cytochrome c oxidase (CcO)42 by involving two accessory factors
Cox11 and Sco1. Cox17 is found within mitochondrial intermembrane space (IMS) and
acts as a copper donor to both Sco1 and Cox11.

43

Cox17 contains conserved cysteines

that makes the protein to have up to three three different oxidation states in the IMS. A
fully oxidized Cox17 has three disulfide bonds, partially oxidized Cox17 has two
disulfide bonds while a fully reduced Cox17 is without any disulfide bond.44,45 The fully
oxidized state of Cox17 has no free thiols and is not able to bind copper, the partially
oxidized form of Cox17 can bind one copper ion because the other cysteine residues are
involved in disulfide bonds. 44, 46
Cox17 is a protein made of 69 amino acid residues. The N-terminal portion has about 20
residues that forms unstructured segment followed by two α- helical hairpin domain
(Figure 1.3).22,46, 47
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Figure 1.3 Solution structure of Cox17 made of coil
coil-helix. Two disulfide bonds stabilize the domain.

The molten globular state of Cox17 is fully reduced and binds four Cu(I) ions with the six
cysteine residues. 44,48
In addition to Cox17, three other proteins, Cox11, Cox19 and Sco1 mediate the delivery
of copper to cytochrome c oxidase-Cco (Figure 1.1). Cox 7 was the first protein to be
identified in copper ion delivery to Cco.42

The functional importance of Cox17 is

evidenced in yeast where mutants of Cox17 are deficient in respiratory growth and Cco
activity. 42 Sco1 is an integral inner membrane protein with a single transmembrane helix
and a globular domain projecting into the IMS.49 Cells with null Sco1 have diminished
Cco activity and are deficient in respiration.
Cox11 is found both in eukaryotes and in gram-negative bacteria. Cox11 has a highly
soluble domain that has an N-terminal fragment anchoring the protein to the membrane.
8

Banci et. al. solved the solution structure of the Cox11 from Sinorhizobium meliloti. The
apo form has an immunoglobulin-like fold which is β-barrel structure.50 The importance
of Cox11 was first demonstrated by Tzagoloff,. Yeast lacking Cox11 have no CcO
activity and are deficient in heme a.51 Hiser et al. have demonstrated that Cox11 may
function primarily in the formation of the CuB site of Cco.52 Cox11 may also function as
a co-chaperone that facilitates the delivery of copper to Cco through another molecule.
Yeast Cox11 is a 34-kDa protein that is anchored by a single transmembrane domain to
the inner mitochondrial membrane. It is dimeric both in the apo and Cu(I) bound form.53

Figure 1.4 solution structure of
Cox11

It binds one copper ion per monomer with three conserved cysteine residues.53
1.2.4 CCS1
Ccs1 is a copper metallochaperone for Cu, Zn-superoxide dismutase. Ccs1 is made of
three domains. Domains 1 and 3 bind Cu(I) while domain 2 interacts with Sod1.54,55 Ccs1
is present in many organisms. Studies have shown that Ccs1 is required for activation of
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Sod1 in yeast,56,11 Drosophila melanogaster,57 and mice.58 Binding of Cu(I) to Ccs1
induces activation of the reduced monomeric Sod1 and facilitates the formation of a
disulfide bond between Cys57 and Cys146.59 The stability of this disulfide bond is
postulated to be due to both the low solvent accessibility of Cys146 and the dimerization
of Sod1. Upon reduction of the disulfide and in the absence of the metal cofactors, the
Sod1 dimer is destabilized and exists as an inactive monomer.59 Ccs1 has three domains.
The N-terminal domain has a βαββαβ fold, similar to Atx1, and is capable of binding one
Cu(I) ion.60 Domain 1 of yeast Ccs1 is not essential for normal growth, but is required
for the activation of Sod 1.56

Domain 2 has an eight-stranded β-barrel structure,

analogous to Sod1.61 In humans, domain 2 of Ccs1 has a Zn(II) binding site, but lacks the
ligand for copper coordination. In yeast, domain 2 of Ccs1 lacks both the Zn and Cu
binding sites.

Domain 2 of Ccs1 is required for docking during the activation of

Sod1.62,63 Domain 3 is found in the short segment of C-terminal. This domain contains a
CXC motif for metal binding, disulfide formation or activation of Sod1.56, 64

1.2.5 Serum Ceruloplasmin
Human serum ceruloplasmin (hCp) is a copper-containing glycoprotein that belongs to a
family of multi-nuclear “blue” copper oxidases. Cp also called iron ferroxidase and it is
involved in iron metabolism. It was first isolated in 1948.65 It has a single polypeptide
chain of 1046 amino acid residues. A glycosylphosphatidylinositol (GPI)-anchored form
of Cp is expressed in the mammalian central nervous system (CNS), while the secreted
form is expressed by the liver released in serum.66,67 The GPI-Cp plays a role in iron
homeostasis and antioxidant defense, where it converts the toxic ferrous iron into the
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nontoxic ferric form68,69 CP belongs to a multicopper oxidase family of enzymes that is
characterized by the presence of three types of spectroscopically distinct copper sites.70
The type I copper sites have charge transfer between the sulfur ligand of cysteine and the
Cu(II) center. Type II copper sites have copper coordinated to four imidazole nitrogens.
The type II and type III copper sites form a trinuclear copper cluster at the interface of
domain one and six.71 In addition to the three copper ions in the trinuclear cluster, three
coppers are found in three mononuclear sites in domain 2, 4 and 6. In each of the
mononuclear sites two histidine residues and a cysteine coordinate the copper ion with an
additional methionine ligand in domain 4 and 6.6
Cp has four known functions. It plays a role in copper transport, and ferroxidase and
amine oxidase activity, and also functions as an antioxidant by preventing the formation
of free radicals in the serum.
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Figure 1.5. Crystal structure of human ceruloplasmin. PDB ID: 1KCW

Although ceruloplasmin requires copper for its function, the mechanism of the secretory
compartment by which copper is incorporated into newly synthesized ceruloplasmin is
unknown. When copper is not incorporated it leads to production of apo-ceruloplasmin,
which has a short half-life of about five hours in the blood.72, 73

1.2.6 P-type ATPases
P-type ATPases are integral membrane proteins that use ATP energy to maintain metal
ion homeostasis, electrochemical gradients and lipid bilayer asymmetry in cells.74,
12

75

There are 11 classes of the P-type ATPase superfamily.76 Class IB (PIB) is the largest and
found in many prokaryotic and eukaryotic organisms.77,78 They are essential for cellular
regulation of heavy metals such as Co(II), Zn(II) and Cu(I).

79

Due to their toxic nature,

these metals are tightly regulated and have extremely low intracellular concentrations.
Cu(I) transporting ATPases are the most prevalent PIB ATPases.79 They are required for
the regulation of copper metabolism in many organisms. In humans there are two Cu(I)transporting PIB ATPases, ATP7A and ATP7B. Defects or mutation in these proteins
cause Menkes and Wilson’s disease, respectively.80 Their up-regulation may cause
resistance to cancer chemotherapy and Alzheimer’s disease.81,82
1.2.6.1 Copper efflux transporters: Menkes protein, Wilson disease protein, PfCuPATPase
Wilson disease protein (ATP7B) transports copper into the secretory pathway for
subsequent incorporation into ceruloplasmin and excretion into bile.83 When there is an
increase of copper concentration in the hepatocytes, the Wilson disease protein
translocates from the trans Golgi network (TGN) to sequester excess copper in
cytoplasmic vesicular compartment near the membrane, and copper is excreted into the
bile.84 When copper concentration decreases, ATP7B returns to the TGN. The copper
dependent movement of ATP7B provides a sensitive mechanism of copper homeostasis
by hepatocytes. Mutations in the ATP7B gives rise to impaired biliary copper excretion
and decreased serum ceruloplasmin.85
The proteins associated with Menkes (ATP7A) and Wilson (ATP7B) diseases are integral
membrane proteins of the PIB ATPases that couple ATP hydrolysis with transport of
copper (I) ions across the membranes.86,80,87,88 Mutation in ATP7A and ATP7B cause
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genetic disorders of copper metabolism leading to copper starvation

or toxicity,

respectively. Both the ATP7A and ATP7B have similar structural features. Their N
terminal region is composed of six metal binding domains (MBDs). These MBDs interact
with and are able to receive copper ions from the copper chaperone HAH1.

1.2.6.2 Menkes disease protein
ATP7A is an X-linked inherited neurodegenerative childhood disorder caused by the
absence or dysfunction of a P-type ATPase (ATP7A) encoded on the X chromosome. It
delivers copper to the secretory pathway of eukaryotic cells.89 ATP7A is located in the
chromosome at Xq13.2-13.3 and has 23 exons that span approximately 150 kb.

89,90

The

ATP7A gene is expressed in all tissues except the liver. Mutations in the ATP7A gene
results in poor distribution of copper to the body's cells. The result is accumulation of
copper in some tissues, such as the small intestine and kidneys, while the brain and other
tissues have unusually low levels of copper.91 Low levels of copper may reduce the
activity of many copper-containing enzymes that are required for the structure and
function of bone, skin, hair, blood vessels, and the nervous system. Mutations that impair
the function of ATP7A gives rise to Menkes syndrome, which is characterized by sparse,
kinky hair, loss of weight and deterioration of the nervous system.92

1.2.6.3 Wilson disease protein (ATP7B)
ATP7B is a genetic disorder of copper homeostasis that is characterized by the excessive
accumulation of copper metal in the liver. ATP7B is a copper transporting P-type
ATPase that is predominantly expressed in the liver, that results from mutations in the
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ATP7B gene.93 ATP7B has eight transmembrane domains that form a channel through
which copper ions pass across the membrane. In hepatocytes, the copper is transferred to
the ferroxidase ceruloplasmin and secreted into the serum.93 Subcellular localization of
ATP7B varies according to changes in the copper concentrations. At low copper levels,
the protein is localized at the Golgi compartment where it is believed that copper loading
of ceruloplasmin takes place.

94,85

When copper levels increase, ATP7B translocates to

cytoplasmic dispersed vesicles.85,95,96 The vesicles transport copper to the bile for
eventual excretion. 97,98
ATP7B has characteristic features of P-type ATPases. The N-terminal domain has six
heavy metal binding domains (MBDs) with the MXCXXC motif, which form the metal
binding site.99, It also has eight transmembrane domains with a CPC motif within the
sixth membrane domain, which facilitates the translocation of the cation through the
membrane.100,101
In addition to the heavy metal binding domains, ATP7B has other cytosolic domains. The
ATP binding domain is subdivided into two subdomains: the phosphorylation domain (Pdomain containing the DKTGT motif)102 and the nucleotide-binding domain (N-domain
containing the GDGIND motif).103 The actuator domain (A-domain) located between the
fourth and fifth transmembrane helices, initiates the phosphorylation process of ATP7B.
The topology of N-domain is βααβββααββ consisting of a central six-stranded antiparallel β-sheet and two α-helical hairpins, one on each side of the β-sheet.104
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Each of the N-terminal metal binding domains has a ferredoxin fold and are connected by
linkers between them.105 Figure 1.6 shows a double ferredoxin fold of domains 5 and 6
of ATP7B.

Figure 1.6. Metal binding domains 5 and 6 of Wilson disease protein each with a
ferredoxin fold.

The number of N-terminal domains of varies between species. For instance, in yeast, the
ATP7B homologue known as Ccc2 has only two metal binding domains and can bind
maximum of two copper ions.106 The Caenorhabditis elegans homolog contains three
metal binding domains,

107

while rat has 6 domains, with one lacking the MXCXXC

motif.108
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1.2.7 The transfer of copper from the HAH1 chaperone to the metal binding
domains of ATP7B
HAH1 is a copper chaperone that delivers copper ions to the metal binding domains of
ATP7B. It has 68 amino acids residues and a molecular weight of 7.5 kDa. Its structure is
a ferredoxin fold (βαββαβ) and has a MTCGGC motif similar to the metal binding
domains of ATP7B. Each of the metal binding domains of ATP7B also has about 70
amino acids and a similar sequence and structure. Each domain folds independently and
can bind one equivalent of copper (I) ion.99,109,105,22 It has been proposed that the Nterminal domains of ATP7B play an important role in the tuning of ATP7B activity and
modulating the intracellular trafficking rates of the ATP7B. 98, 110, 111
The transfer of Cu(I) from the chaperone to the MBDs of ATP7B is mediated by a
metal-bridged intermediate.112 In one study, the binding affinity (KCu) of the six MBDs of
ATP7B was found to be higher than the KCu of the metallochaperone HAH1.113 The
copper ion may undergo inter-domain transfer until it is eventualyl transported across
the membrane. The copper ion is then transferred to acceptor protein, ceruloplasmin in
the lumen (Figure 1.28). The transfer of copper(I) to the metal binding domains of
ATP7B has been studied using various methods, such as NMR and metal transfer assays.
Achila and co-workers105 used

a construct containing the last two metal binding

domains(MBD5-6) to study the copper transfer from HAH1 to these domains. Titration
of Cu(I)-HAH1 to the apo MBD5-6 construct revealed that HAH1 does not transfer
copper to domains 5 and 6. There was no copper exchange or complex formation
observed via NMR. Interestingly, this construct was able to receive copper from Cu(I)-
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MBD4 when MBD5-6 was titrated with holo MBD4. It was observed that domain 6
received copper before domain 5, without any complex formation with HAH1.

Figure 1.7. Movement of copper ions across the TGN membrane

Domain 4 also forms an adduct with Cu(I)-HAH, and to a lesser extent with MBD2.
Banci and co-workers22 used solution NMR to study the interaction of Cu(I)- HAH1 with
MBD3-4 of ATP7B. When MBD3-4 was titrated with Cu(I)-HAH1, HAH1 formed a
complex with MBD4, MBD3 also did not acquire copper from HAH1. These
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observations were in contrast with the interaction of MBD1-6 with Cu(I) HAH1.114 Each
domain in this construct was able to receive copper from Cu(I)-HAH1.

However,

domains 1, 2 and 4 were able to form complexes of a copper(I)-bridged adduct with
HAH1 while domains 3, 5 and 6 received the copper metal from the metallochaperone
without accumulation of the protein-protein adduct.22
A separate study by Fatemi and co-workers115 used NMR spectroscopy to probe the
structural and dynamic properties of MBD4−6 and MBD1-6 but their results were not in
agreement studies of Banci et al. They determined that the three domains in the MBD4-6
construct have independent mobility in solution. Domain 4 tumbles independently of
domain 5 and 6. This may be due to the fact that domain 4 is separated by a long linker
from domain 5 while domains 5 and 6 have a shorter linker between them, which limits
their interdomain movements.115 In this study it was found that domains 4, 5, and 6
tumbled independently of each other both in the apo state and Cu(I)-bound state. It was
shown that the construct MBD4-6 interacted with the metallochaperone both in the apo
and holo forms. Domain 4 appeared to have more interaction with HAH1, suggesting that
the transfer of copper from HAH1 to this domain is driven by protein-protein interactions
that occur even in the absence of copper. This may be plausible because domain 4 has a
net negative charge at pH 7 with a pI of 3.81 while HAH1 has a pI of 7.5 and a net
positive charge (theoretical values). The flexible linkers between individual MBDs of
ATP7B suggest that each domain may receive copper from HAH1 independently, with
domain 4 being the most likely to form a complex with Cu(I) bound HAH1. The absence
of domain four in mouse ATP7B108 questions the hypothesis that HAH1 first transfers
copper to MBD4 and that domain 4 subsequently transfers copper to other MBDs. Since

19

both HAH1 and MBDs of ATP7B have a similar structure (βαββαβ ferredoxin folds),37
the presence of complementary charges at the surface of these proteins suggest that
HAH1 forms adducts and transfer the Cu(I) metal ion to the MBDs through ligand
exchange.109

1.2.8 The Wilson disease
Wilson’s disease (WD) is caused by accumulation of copper in major organs due to a
defect in ATP7B. Copper deposition in the cornea results in the Kayser-Fleischer (KF)
ring, a rusty brown ring around the cornea of the eye. There are nearly 500 identified
mutations in ATP7B, and 300 of these mutations have been associated with Wilson
disease.116 The mutation may be at any position of the gene. The most common type of
mutation found in ATP7B is a missense mutation. Genetic mutation of ATP7B gene in
patients with WD vary across various races and geographic regions.117 H1069Q mutation
is the most common in WD patients from European countries such as Sweden, Italy and
Romania.118 R778L is most prevalent mutation in East Asia.119

1.3 Copper metabolism in Plasmodium falciparum
1.3.1 Introduction
Understanding copper metabolic pathways in Plasmodium falciparum will be helpful in
discovering possible copper chelators that may be used in new antimalarial therapy
development. Copper is an essential nutrient that Plasmodium falciparum needs to
colonize its host.120 The cellular copper levels are carefully regulated by a copper efflux
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protein (PfCuP-ATPase) to prevent its toxic levels.120 The work of Asahi et al. shows that
chelation of Cu(I) inhibits growth of Plasmodium falciparum at the ring stage.121

1.3.2 Malaria: malarial parasites, current treatment and drug resistance

Malaria has remained a major threat to the public health and economic development,
especially in tropical regions of the world. The majority of the world’s population lives in
regions where malaria is common. Human malaria is caused by Plasmodium parasites
transmitted by the Anopheles mosquito. There are four plasmodium parasites that cause
malaria: Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and
Plasmodium ovale. Of the four parasites, Plasmodium falciparum is the most lethal.122
Spread of malaria is largely due to the resistance to anti-malarial drugs and insecticides,
lack of proper public infrastructure, movement of population, and environmental
changes.123
Presently, due to the lack of an effective malaria vaccine, control and management of
Plasmodium falciparum based malaria is mediated by antimalarial drugs. 124 This has led
to the spread of drug-resistant Plasmodium falciparum parasites continue to threaten
global malaria control and elimination programs.125 In 2002, it was estimated that
approximately 2.2 billion people were exposed to Plasmodium falciparum malaria, with
300-600 million reported clinical cases. Of these reported cases, 70% were in Africa,
while 25% were in South East Asia.125 Malaria has an annual mortality rate of about a
million.126 In 2010 3.3 billion people were are at risk of acquiring a malaria infection,
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216 million cases of malaria were reported worldwide and 655,000 of the infected died
(WHO Malaria report, 2011). In 2013 there were an estimated 198 million cases and 584,
000 deaths reported (WHO Malaria report, 2014). It is one of the most infectious diseases
mankind has experienced. Malaria infection is predominantly caused by Plasmodium
falciparum.
In many cases the parasite has developed resistance to currently available anti-malarial
drugs. The mechanism of action of some of these drugs, such as artemisin, deferoxamine
and quinolone, is their ability to interact with metal ions and creating free radical
intermediates.127 These metal chelators are believed to inhibit parasite growth though
radical formation.128,

129

Resistance of malarial parasites to some of the existing drugs

requires the need to develop new therapeutic agents.130 Integral membrane proteins
which are metal transporters are increasingly becoming targets for potential drug
development. These proteins are essential for metabolism of metal ions and are required
for the growth and replication of Plasmodium parasites.131 Understanding structure and
function of these proteins will provide valuable information that may be applied in drug
development.
1.3.3 Growth and development of Plasmodium falciparum
Understanding the Plasmodium falciparum stages of growth and development will be
valuable in exploring new ways of interfering with the parasites life cycle.132 Malaria
parasites have a complex life cycle in their two host organisms: humans and female
Anopheles mosquitoes.133,132 The life cycle of malarial parasites is one of the most
complicated and fascinating areas of study in cell biology, molecular biology, and
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immunology of any living organism. The intricate biology of Plasmodium falciparum has
proved to be challenging for researchers for decades and has been a major setback for the
development of a malarial vaccine. As a result, malaria has continued to be a devastating
disease in developing countries, especially is sub-Saharan Africa. Two of the major
challenges in understanding the parasite’s life cycle is its abilities to change its cellular
and molecular makeup, which is controlled by a genome with more than 5000 genes, and
it is interaction with the mammalian host and the mosquito vector.134 The complex
development of malarial parasites may explain why the mode of transmission of malaria
was unknown until the end of nineteenth century.
Initially, in 1903, it was erroneously observed that the sporozoite stage of malarial
parasites directly infects the erythrocytes. This mistake hindered the progress of studies
on the initial stages of the malarial infection in the human host. Four decades later Shortt
& Garnham135 demonstrated that the sporozoites first infects the hepatocytes, and then
the erythrocytes. Much success in understanding the pre-erythrocytic stages of malarial
parasites has been achieved through advancement of gene manipulation technologies and
in vivo imaging.135, 136 Valuable data has now been collected about the various molecular
and cellular mechanisms of sporozoites infection of the liver. The genes that are essential
for the development of the malarial parasites in the liver are being targeted for the
development of potential malarial vaccine.137
In humans, the Plasmodium falciparum parasite’s life cycle begins in the liver, with
subsequent infections of the red blood cells. Parasites in the blood are responsible in
causing malarial symptoms. Parasites, in the form of sporozoites, are injected into the
blood stream by a female Anopheles mosquito while it feeds on human blood.138 These
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sporozoites then travel to the liver where they invade liver cells. In the hepatocytes the
sporozoites grow, divide, and release thousands of haploid forms, called merozoites.139
The merozoites exit the liver cells, re-enter the bloodstream, and invade the red blood
cells. In the red blood cells, they multiply asexually and release newly formed
merozoites. Thousands of parasite-infected cells in the host bloodstream cause the
malarial illness. It is believed that during red blood cell invasion Plasmodium falciparum
merozoites use multiple receptor–ligand interactions to coordinate a series of events.140
Some of the merozoites develop into the a sexual form of the parasite that has male and
female gametocytes. The gametocytes are ingested by a mosquito when it bites an
infected human, and they develop into gametes while in the gut of the mosquito. The
male and female gametes fuse together to form diploid zygotes, which develop into
ookinetes and eventually oocytes. The oocytes grow and divide into form sporozoites.
When the oocytes burst, it releases the sporozoites, which reside in the salivary glands of
the mosquito. When it takes a blood a meal from a human, the sporozoites are injected
into the human blood stream and the cycle re-starts. The host’s fight against Plasmodium
falciparum has been hampered by the complexity of the life cycle of the parasite. The
short-lived extracellular appearance of the merozoites and the intracellular nature of the
other asexual forms makes it extremely difficult for the host to mount an effective
immune response.141

1.3.4 Targeting malarial parasites’ proteins for anti-malarial drugs development
The first genome sequence for the Plasmodium falciparum was published in 1998.123
With the estimated 5,300 genes, researchers around the world aim develop new
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antimalarial drugs, vaccines and diagnostic tests.142,143,144 By 2002 the P. falciparum,
Anopheles gambiae and Homo sapiens genome sequences were also completed. This was
a first milestone in the long search for solutions to the malarial menace. These sequences
provide a wealth of information on parasite biology, including the structure, content of
the genes, proteins classification and function, and transport metabolism pathways within
the parasites.

1.3.5

PfCuP-ATPase: structural organization

PfCuP-ATPase is the largest copper transporter protein with a theoretical molecular
weight of 298kDa. The mass is almost double that of Cryptosporium parvum, Wilson and
Menkes disease protein.120 The higher mass is due to presence of many inserts between
the functional domains.145, 146
Unlike other P-type ATPases, PfCuP-ATPase has a single N-terminal copper-binding
domain with a MXCXXC motif, which binds copper in reduced state. The protein levels
are highest at the trophozoite stage of Plasmodium falciparum growth. The protein is
found both on the parasite’s membranes and on the surface of infected erythrocytes.120
This localization suggests that the protein, much like the Wilson and Menkes disease
proteins, is involved in the secretion of excess copper ions out of the cell. The Wilson and
Menkes disease proteins have six N-terminal domains and are capable of binding up to
six equivalents of copper ions. PfCuP-ATPase however, can only bind one equivalent of
copper ions due to it having one MXCXXC motif for copper binding.120 This copper
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binding site may individually or in co-operation with other domains within the protein,
act as a copper sensor to regulate ATPase transcription in response to copper levels.
PfCuP-ATPase is a protein with many puzzling features uncharacteristic of P type
ATPases. For instance, the N-terminal metal binding domain has only one MXCXXC
motif yet has about 565 amino acids residues. The size of this region is almost equal to
the N-terminal domain of Wilson disease protein. Wilson disease protein has six
functional metal binding domains in the N-terminal domain. PfCuP-ATPase also has 10
predicted transmembrane domains relative to the 8 domains of ATP7B, however, the two
additional transmembrane domains have yet to be verified. 120

1.3.6

PfCuP-ATPase expression levels in different stages of Plasmodium falciparum
life cycle

Rasoloson et al. used an affinity purified MBP-MBD antibody to determine the
localization of the PfCuP-ATPase. They discovered that PfCuP-ATPase is expressed in
the trophozoite stage of Plasmodium falciparum growth. The protein was not detected in
either the uninfected red blood cell or the ring stage. It was determined that protein
expression was visible on the surface of infected erythrocytes and on the parasite’s
plasma membrane.120 This result implies that two separate mechanisms are used to
transport copper out of the parasite; one involves in the transport of copper ions to the
plasma membrane of the parasite and another pathway involves the transport of the metal
ion from the parasite plasma membrane to the erythrocyte’s surface and eventual efflux.
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A later study by Kenthirapalan et al. revealed the PfCuP-ATPase is expressed in all
Plasmodium life cycle stages and localizes to vesicle-like structures that might represent
storage vesicles.147 The investigators showed through live imaging of the PfCuP-ATPase
containing parasites that PfCuP-ATPase was expressed in both asexual and sexual stages
in the blood. The protein also consistently localizes in vesicle-like structures in the
parasite’s cytoplasm. The origin of these vesicular like structures remains unknown.

1.4 Research objectives
The main research goal is to understand the structural basis of the N-terminal metal
domains of copper ATPases by studying four copper proteins in different organisms:
Human Wilson disease protein (ATP7B), Dictyostelium discoideum copper ATPase
(DdATP1), Dictyostelium discoideum copper chaperone (DdAtox1), and Plasmodium
falciparum copper ATPase (PfCuP-ATPase).
The cytosolic domains of the metal binding portion, actuator, nucleotide and
phosphorylation domains of Wilson disease protein have been studied by NMR.
However, the structure of a complete protein has not been determined. There are gaps in
the literature on the structure of the copper ATPase and how it couples ATP energy with
copper transport. A homologous structure of ATP7B form Legionella pneumophila has
been solved by X-ray crystallography.148 Although this structure details the structural
organization of ATP7B, the metal binding portion of the protein was missing in the
structure. Furthermore, the protein has not been expressed in E. coli. Recombinant
expression of the ATP7B and the eventual atomic structure determination will help
answer key questions of how the enzyme transports copper, how the cytosolic copper is
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loaded into the metal binding domains, and the shuttling of the metal ion across the
membrane and the effects of mutation on the structure and function of the protein. One of
my research goal was to clone the full length Wilson protein by recombinant DNA
technology and express the protein in E. coli for biophysical characterization. In order to
better understand the mode of interaction of the N-terminal domains of ATP7B with its
copper donor, HAH1, I engineered a chimera of the fourth metal binding domain four of
ATP7B and copper chaperone HAH1 and expressed it in E. coli. The aim of this project
was to crystallize the chimera in the presence of copper metal with the hope of obtaining
a structure that shows the complex formation between the two proteins. The results of
this project were expected to shed more light on the mechanism of adduct formation of
the copper chaperone HAH1, and metal binding domains of ATP7B.
A second project was undertaken to study the N-terminal domains of Plasmodium
falciparum copper P type ATPase. Despite copper being found to be essential in the
growth and development of Plasmodium falciparum, and the discovery of PfCuP-ATPase
as a copper transport protein involved in the metabolism of the metal ion in Plasmodium
parasites, the structural organization of the ATPase has not been determined. To better
understand its structure and function I pursued biophysical studies of the the N-terminal
domains of PfCup-ATPase using bioinformatics analysis, circular dichroism, metal
binding studies and solution NMR. The goal of this project was to determine the number
of the N-terminal domains, the copper binding affinity of PfCuP-ATPase, and determine
the structures of these domains. The findings of this study were expected to highlight the
structural organization of the ATPase.
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A third project was to define the N-terminal domains of Dictyostelium discoideum
copper ATPAse (DdATP1). Dictyostelium discoideum is a social amoeba that inhabits
forest soils. Its main food source is bacteria. It is speculated that the organism uses
copper and zinc as its brass dagger, during feeding, where copper is thought to be involed
in bacterial killing in the phagosome of the amoeba. The structure and function of this
protein is little known. Using protein bioinformatics tools, two metal binding domains
were identified in the N-terminal portion of the copper ATPase. The goal of this project
was to clone and express the individual domains in E. coli and determine the copper
binding affinity of the N-terminal domain of DdATP1 and compare with that of its
copper donor, Atox1 (DdAtox1). The results of this project are expected to help us
understand the chemistry of phagocytosis.
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CHAPTER 2
MATERIALS AND EXPERIMENTAL METHODS FOR CLONING AND
EXPRESSION OF WILSON DISEASE PROTEIN

2.1 Introduction
This chapter describes in details all the reagents, biological supplies, equipment as well
as procedures followed for plasmids preparation, protein expression and purification.

2.2 Chemical reagents, plasmids, kits and instrumentation
This section describes the chemical reagents and kits that were used for all experiments.
Separate tables contain the list of these materials used.

Table 2.1 Chemical reagents
Chemical reagent

Catalog number

Supplier

Agar
Agarose
Acrylamide
15
N Ammonium chloride
Ammonium persulfate

J637-5
16500-100
A0268205
NLM-467-1
BP179-100

MIDSCI
Acros Organics
Invitrogen
Cambridge
Fisher Scientific

Ampicillin
Bis-Acrylamide
Boric Acid
Bromophenol Blue
13
C Glucose
Coomasie Blue R-250
Dibasic sodium phosphate
Dithiothreitol (DTT)
EDTA
Glycerol

A-9518
BP171-25
BP168-1
B-6131
CLM-1396-1
20278
S-5136
1758-9030
H45476
G33-1

Sigma-Aldrich
Fisher Scientific
Fisher Scientific
Sigma Aldrich
Cambridge Isotope
Thermo Scientific
Sigma Aldrich
Inalco Sas
Mallinckrodt chemicals
Fisher Scientific
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Purity

99%
>99%
Isotope
Electrophoresis
grade
>92.5%
>99%
>99%

99.7%
99.9%

Table 2.1 Chemical reagents – Continued
Chemical reagent

Catalog number

Supplier

Purity

Guanine hydrochloride
HEPES
Imidazole
IPTG
Kanamycin sulfate
Magnesium chloride
MES
Methanol
Monobasic sodium
phosphate
Nickel (II) Sulfate
Sodium chloride
Sodium dodecyl sulfate
(SDS)
Sodium hydroxide
TEMED
Thiamine HCl
Tris base
Tryptone
Urea
Xylene cyanol FF
Yeast extract

G3272-500G
BDH4518-1KG9
A10221
1758-1400
420311
BP214-500
BDH4544

>99.5%
>99.9%
99%

BP330-1

Sigma Aldrich
VWR
Alfa Aesar
Inalco Sas
Calbiochem
Fisher Scientific
VWR
Sigma Aldrich
Fisher Scientific

211085000
BDH0286-500G
15525-017

Acros Organic
VWR
Gibco

99%
>99%
>99.5%

S612-3
BP150-100
BP982-100
BP152-5
1211-1
BP169-500
BP565-10
DF0127071

Fisher Scientific
Fisher Bioreagents
Fisher Scientific
Fisher Scientific
Mo Bio Labs
Fisher Scientific
Fisher Scientific
Fisher Scientific

>99%
>99%
99.8%
98%

>97%

99%
Biotech grade

Table 2.2 Biological reagents, Enzymes and purification kits
Enzymes and kits
BamHI
BglII
Benzonase
Bio-Rad protein assay reagent
BCA protein assay kit
BL21(DE3) competent cells
1 Kb DNA Ladder
KOD Hot Start DNA Polymerase
MiniElute PCR Purification Kit

Catalog number
NS3231S
R0144S
70746
500-0006
23225
69450
N3232S
71086-3
28004

Supplier
NEB
NEB
Novagen
Bio-Rad
Thermo Scientific
EMD Millipore
NEB
Novagen
Qiagen

NotI
NcoI

R0189S
R0193S

NEB
NEB
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Table 2.2 Biological reagents, Enzymes and purification kits – Continued
NovaBlue competent cells
QIAquick Gel Extraction Kit
QIAquick Spin Miniprep Kit
Quick Change II Site-Directed Mutagenesis Kit
Rainbow Protein marker
Rosetta (DE3) competent cells
Fast-Link DNA Ligation Kit
Gel Filtration Calibration Kit LMW
TEV encoding plasmid

71227-3
Novagen
28706
Giagen
27106
Qiagen
200521-5
Stragene
RPN800E
GE
70954-3
Novagen
LK0750H
Epicentre
28-4038-41
GE Healthcare
Kind gift from Dr. Timothy A. Cross,
National High Magnetic Field Laboratory,
Florida State University

ATP7B, CDNA for Wilson disease protein

Generous donation from Dr. Jonathan
Gitlin, Marine Biological Laboratory, Wood
Hole

Table 2.3 Proteins Notation (Plasmodium falciparum copper P-type ATPase)
Notation
PfCuP-MBD1
PfCuP-MBD2

Protein name
N-terminal domain 1
N-terminal domain 2

PfCuP-MBD2-3

N-terminal domain 2-3

394-564

513

PfCuP-MBD3
DdCuP-MBD1

N-terminal domain 3
N-terminal domain 1 with
CX3C motif
N-terminal domain 2 with
CX2C motif
N-terminal domains 1-3 of
human ATP7B
N-terminal domains 1-4 of
human ATP7B
Chimera of WLN domain 4
and HAH1 chaperone
Dictyostelium discoideum
copper metallochaperone

481- 564
205- 272

252
204

356- 425

210

57-327

813

57-431

1125

356-487 of ATP7B
and 1-68 of HAH1
1-68

600

DdCuP-MBD2
WLN1-3
WLN1-4
WD4-HAH1
DdAtox1

Residue number
1-70
394-470
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Number of base pairs
210
231

207

2.3 PCR primers
All PCR primers were purchased from Integrated DNA Technologies, Inc. Table 2.4
contains a list of all primers used for the gene amplification of various protein constructs
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Table 2.4 PCR primers
Primer
PfCuP-D1 BamHI Fwd

bp
54

%GC
51.9

TM °C
70.3

55

PfCuP-D1 BamHI Rev

54
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70.1

PfCuP-D2 Fwd
N-terminal His tag
PfCuP-D2
N-terminal His tag
Reverse primer
PfCuP-D2
C-terminal His tag
Forward primer
PfCuP-D2
C-terminal His tag
Reverse primer
PfCuP-D2
With Trx fusion tag
Forward primer
PfCuP-D2
With Trx fusion tag
Reverse primer
PfCuP-D2 and PfCuP-D2-3
Poly glycine
Forward primer
PfCuP-D2 and PfCuP-D2-3
Poly glycine
Reverse primer

60

58.3

74.4

43

53.5

68.2

Sequence 5’ to 3’
CAGAGCGACGCCATGGCAAAACTGTCGCTGACGATCAATA
ATGTGGACGATGAC
CGCAAGCTTGCGGATCCATGCTCATTTGCTGCTAATGTCGTTG
TCGTCTTTCAG
CGACGCATGCCATGGATGCATCACCACCACCACCACAGCGGG
ATTGAGGGTCGCGAAAAT
CGCGGATCCGCGTTCAGTCATCTTTATACAGGTCCAGCAGATC

42

47.6

66.3

CGGACGCATGCCATGGATTACATCTGCGAACTGAAAATCTAC

60

43.3

68.3

CGCGGATCCTCAGTGGTGATGGTGATGGTGACCTTGAAAATA
TAGATTTTCGTCATCTTT

60

38.3

65.9

GGTATTGAGGGTCGCGAAAATCTATATTTTCAAGGTTACATC
TGCGAACTGAAAATCTAC

41

46.3

64.3

AGAGGAGAGTTAGAGCCTCAGTCATCTTTATACAGGTCCAG

45

57.8

71.3

CTATATTTTCAAGGTGGCGGCGGCGGCGGCTACATCTGCGAA
CTG

45

57.8

71.3

CAGTTCGCAGATGTAGCCGCCGCCGCCGCCACCTTGAAAATA
TAG

Table 2.4 PCR primers – Continued
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PfCuP-D2 and PfCuP-D2-3
Insert three glycine
Forward primer
PfCuP-D2 and PfCuP-D2-3
Insert three glycine
Reverse primer
PfCuP-D2 and PfCuP-D2-3
Insert Threonine at P2
Forward primer
PfCuP-D2 and PfCuP-D2-3
Insert Threonine at P2
Reverse primer
PfCuP-D2 and PfCuP-D2-3
Insert Valine at P2
Forward primer
PfCuP-D2 and PfCuP-D2-3
Insert Valine at P2 Reverse
primer
PfCuP-D2-3
C-terminal His tag
Forward primer
PfCuP-D2-3
C-terminal His tag Reverse
primer
PfCuP-D2-3 With TRX
fusion tag, Forward primer

36

47.2

63.9

CTATATTTTCAAGGTGGCGGCTACATCTGCGAACTG

35

47.2

63.9

CAGTTCGCAGATGTAGCCGCCACCTTGAAAATATAG

33

42.4

60

CTATATTTTCAAGGTACCTGCGAACTGGAACTG

33

42.4

60

CAGTTCCAGTTCGCAGGTACCTTGAAAATATAG

33

39.4

58.6

CTATATTTTCAAGGTGTCTACATCTGCGAACTG

33

39.4

58.6

CAGTTCGCAGATGTAGACACCTTGAAAATATAG

42

47.6

66.3

CGGACGCATGCCATGGATTACATCTGCGAACTGAAAATCTAC

60

43.3

68.1

CGCGGATCCTCAGTGGTGATGGTGATGGTGACCTTGAAAATA
TAGATTTTCGTTGTTTTG

60

38.3

65.9

GGTATTGAGGGTCGCGAAAATCTATATTTTCAAGGTTACATC
TGCGAACTGAAAATCTAC

PfCuP-D2-3 With TRX
fusion tag, Reverse primer

41

48.8

66.5

AGAGGAGAGTTAGAGCCTCATTCGTTGTTTTGTGAGGAGCG

Table 2.4 PCR primers – Continued
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PfCuP-MBD3
Forward primer
PfCuP-D3
Reverse primer
Wilson protein
Forward primer:

54

50

69.9

48

50

68.9

54.5

71.6

Wilson protein
Reverse primer (with Not1):
Wilson protein
Reverse primer (with BamH1):

60

53.3

72.1

60

46.7

68.6

HAH1 Xma1 mutation Forward

39

53.8

68.3

GGTTGCGCTGAAGCTGTATCGCGCGTACTGAACAAACTG

HAH1 Xma1 mutation Reverse

39

53.8

69.3

CAGTTTGTTCAGTACGCGCGATACAGCTTCAGCGCAACC

WD4 Xma1 mutation Forward

33

57.6

69.3

ACCAGAGCAGTGCCCGGGCAGAAGTGCTTCTTA

WD4 Xma1 mutation Rverse
HAH1 Forward

33
62

57.6
61.3

69.3
74.7

HAH1 Reverse

43

62.8

73.3

TAAGAAGCACTTCTGCCCGGGCACTGCTCTGGT
GCGCCCCCCCGGGCCGAAACACGAATTCTCTGTAGACAT
GACTTGCGGTGGTTGCGCTGAAG
GGCAGCAGCCAACTCAGCTTCCTCCCGGGCTTTGTTAGCAGCC

55

CGAGCGACGCATGCCATGGATGACAAAAATCGTTGTAACCT
GTCGGAAATCACC
CGCGGATCCGCGTCATTCGTTGTTTTGTGAGGAGCGGAAGTA
TTTTTC
GGGCCGCGGATCCGAAAATCTATATTTTCAAGGTGTGGCCAC
CAGCACAGTCAGG
GCCTGCCgcggccgcACCTTGAAAATATAGATTTTCcCAGATGTA
CTGCTCCTCATCCCT
CCTGCCTGAGGATCCCAACCTTGAAAATATAGATTTTCGATGTAC
TGCTCCTCATCCCTG

TRX: Thioredoxin fusion tag
P2: Position two of TEV protease recognition site (ENLYFQG.), Glycine residue (G) is at position 1
Poly Glycine: Six Glycine residues

2.4 Instrumentation
This section describes the instruments their usage and the source of the instruments.
These details are described in tables 2.5 and 2.6
Table 2.5 Instrumentation, source and usage
Instrument
AKTA FPLC
AKTA Prime plus
Analytical balance

Usage
Protein purification
Protein purification
Weight
measurements >
0.1mg

Model
18-1900-26
03-0014-96
AT400

Manufacture
GE life sciences
GE life sciences
Mettler Toledo

Analytical balance

Weight
measurements >
0.1g
Circular Dichroism
measurements
Performing
experiments under
anaerobic
conditions
PCR
1
H-15N HSQC and
Triple resonance
experiments
1
H-15N HSQC
experiments

PG603-SDR

Mettler Toledo

J-815

JASCO

Bruker

AVANCE II, 800
MHZ

Determination of
[GuHCl]
Storage of samples
at -80°C

Bausch and Lomb

Abbe 3L

HARRIS

B65066A

pH benchtop meter

pH measurements

Shaker/Incubator

Thermo electron
corporation
New Brunswick
Scientific
ICB 0052

Growth of bacterial
culture
Growth of bacterial
colonies
Quantification of
DU-7400
DNA and Protein in
solution

Orion 3 star pH
benchtop
Innova 4300

CD
Spectrophotometer
Glove box

MiniCycler
NMR facility at
Michigan State
University
NMR facility at the
University of Notre
Dame
Refractometer
Freezer

Gravity Convection
Incubator
UV-VIS
Spectrophotometer

MJ research
Varian
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Vacuum
atmosphere
NEXXUS chamber
under nitrogen
PTC 150
Unity Inova 600
MHZ

Precision
Beckman

Table 2.6 Columns used for protein purification (GE Life Sciences)
Column
CM Sepharose XK
26
DEA Sepharose XK
26

Usage
Cation exchange
purification
Anion exchange
purification

Resin
Carboxy methyl
sepharose
Diethyl amino
sepharose

Part number
56-1053-34

HiPrep 26/10
Desalting column
HisPrep FF 16/10

Buffer exchange

17-5087-01

His tag affinity
purification

Superdex G-25
superfine
Ni Sepharose 6 Fast
Flow

HiLoad 26/60
Superdex 75 pg

Size exclusion
chromatography

Superdex 75 Prep
grade

17-1070-01

HiLoad 16/600
Superdex 75 pg

Determination of
apparent molecular
weight

Superdex 75 Prep
grade

28-9893-33

56-1053-34

28-9365-51

Table 2.7 Plasmids used for the protein constructs
Plasmid
pET24d(+)
pET28b(+)
α-pET28a (+)pET28a (+)-α
α-pET28a (+)-α
α-pET28a (+)-β

β-pET28a (+)-α
β-pET28a (+)-β

Characteristics

Source

Expression of protein without
fusion tag
Expression of protein with Cterminal His tag
Expression of protein with a Nterminal YaiN (α ) fusion tag
Expression of protein with a Cterminal YaiN (α ) fusion tag
Expression of protein with a both
N and C-terminal YaiN (α ) fusion
tags
Expression of protein with
a N-terminal YaiN (α ) and Cterminal YbeL (β ) fusion tags
Expression of protein with a Nterminal YbeL (β ) and YaiN (α )
fusion tags
Expression of protein with a Nterminal YbeL (β ) and C-terminal
YbeL (β ) fusion tags

Novagen

59

Novagen
Kind gift from Prof.
Nathan Nelson
Department of
Biochemistry, The
George S. Wise
Faculty of Life
Sciences, Tel Aviv
University, Tel
Aviv 69978, Israel

Table 2.7 – Continued
β-pET28a (+)
pET28a (+)-β
pET32Xa/LIC

Expression of protein with a Nterminal YbeL (β ) fusion tag
Expression of protein with a Cterminal YbeL (β fusion tag
Expression of Thioredoxin fusion
tagged proteins

2.5 Amino acid sequences
2.5.1 Plasmodium falciparum PfCuP-ATPase constructs
PfCuP-D1 Amino Acid Sequence
1
MAKLSLTINNVDDDLKRKIKKAKFEGVEDLKHKNKKLTISYNPKVVDSYGVIERI
KHLDINGEILKDDNDISSK74
Length; 70 residues, MW; 8066 Daltons
Figure 2.1 Amino acid sequence of PfCuP-D1

394

YICELKIYNMTCDNCGKKIINFLKDKKLILEGNSFATDNKIKLKIDISSDIIHCNNN
VKMFVNTIMNEIKESGFNNDLLDLYKDD478
Length; 84 residues, MW; 9854 Daltons
Figure 2.2 Amino acid sequence of PfCuP-MBD2

477

DDKNRCNLSEITLYIYRDDIKKSYKLLKDIKGISNVEYDLKKEYIYFLYDPELVGI
RYILEILKKKKNVDAYYDEDKEKYFRSSQNNE564
Length; 88 residues, MW; 10779 Daltons
Figure 2.3 Amino acid sequence of PfCuP-D3
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394

YICELKIYNMTCDNCGKKIINFLKDKKLILEGNSFATDNKIKLKIDISSDIIHCNNNV
KMFVNTIMNEIKESGFNNDLLDLYKDDKNRCNLSEITLYIYRDDIKKSYKLLKDIKGI
SNVEYDLKKEYIYFLYDPELVGIRYILEILKKKKNVDAYYDEDKEKYFRSSQNNE564
Length; 171 residues, MW; 20385 Daltons

Figure 2.4 Amino acid sequence of PfCuP-D2-3. PfCuP-D2 (green), linker (blue),
PfCuP-D3 (red), linker between PfCuP-D3 and the first predicted transmembrane domain
(purple).
2.5.2 Dictyostelium discoideum ATP1 constructs
203

SRERVFEIKGMKCEVGCANRIEATLLQNKNIHSVKINFKTKQLFVIASVNDRTIRKTI
EKLGFKCQKQ270
Length; 69 residues, MW; 7938 Daltons
Figure 2.5 Metal binding domain 1 of Dictyostelium discoideum ATP1 amino acid
sequence
356

IISIGVFGMTCASCVGMVEHSIKSVDGVIECNVNLLAERAEIKYNSSICKDVKEIQESI
EILGFETKLIQQSKAG430
Length; 75 residues, MW; 8176 Daltons
Figure 2.6 Metal binding domain 2 of ATP1 amino acid sequence
2.5.3 Dictyostelium discoideum Atox1
MGTYSFFVDMTCGGCSKAVNAILSKIDGVSNIQIDLENKKVSCESSKMGADELLKNIQ
KTGKKCSIIA
Length; 69 residues, MW; 7263 Daltons
Figure 2.7 DdAtox1 amino acid sequence
2.5.4 Chimera of Wilson protein domain 4 and HAH1(WD4-HAH1)
GTCSTTLIAIAGMTCASCVHSIEGMISQLEGVQQISVSLAEGTATVLYNPAVISPEELRA
AIEDMGFEASVVSESCSTNPLGNHSAGNSMVQTTDGTPTSLQEVAPHTGRLPANHAP
DILAKSPQSTRAVMPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIES
EHSMDTLLATLKKTGKTVSYLGLE
Length; 199 residues, MW; 20677 Daltons
Figure 2.8 WD4-HAH1 amino acid sequence
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2.6 Procedures
2.6.1

Plasmids construction, protein expression and purification

2.6.1.1 Plasmid construction of a full length ATP7B

Overexpression of membrane proteins (MP) in E. coli is challenging. In fact, the
expression of membrane protein in E. coli often leads to their aggregation and reduced
levels of host membrane and secretory proteins.1 MP toxicity is due to the overloading of
the Sec-dependent translocation machinery, which handles both the post-translational
export of secretory proteins and the co-translational insertion of most inner MP into the
lipid bilayer.2 One approach, however, has been to make use of E. coli strains C41 (DE3)
and C43 (DE3), which tolerate the accumulation of toxic proteins. Another common
method that can enhance overexpression of MP in E. coli is the use of fusion proteins.3,4
The genetic fusion of the protein of interest to the N or C termini of other proteins can
yield higher expression, increase solubility and simplify detection and affinity
purification of the overexpressed products.3
Full length ATP7B has 1465 amino acid residues. The gene containing the ATP7B was
amplified by PCR using primers designed such that the first 57 residues were omitted.
These residues were removed since they were predicted to be unstructured. The gene was
amplified from pCDNA containing the full length ATP7B gene. The PCR reaction was
done using the KOD Hot Start DNA polymerase protocol, Table 2.63 (a) and (b). The
primers were designed such that either the forward, or reverse primers encodes for the
Tobacco Etch Virus (TEV) protease recognition site. Both forward and reverse primers
include a sequence compatible with pET28a (+) vector. pET28a (+) derived expression
vectors were originally engineered by Leviatan et al.5 to contain bacterial fusion domains
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at either the N, C or both termini of the gene of interest. This expression cassette for
proteins was expected to increase the chances that membrane protein overexpression will
be successful. The fusion domains are two short hydrophilic bacterial proteins YaiN and
YbeL, (denoted as α and β) proteins, respectively. When fused to the end of membrane
proteins they serve as facilitators for expression and purification. The α and β domains
are hydrophilic and possess globular structure. The α fusion domain belongs to the E.coli
operon frm, which is likely involved in the degradation of formaldehyde.6 The β fusion
domain is composed of the first 120 amino acid residues of the E. coli β gene that has no
known function.7 The PCR product for the ATP7B gene that was inserted into pET28a(+)
was 4235 bp, and was purified by gel extraction kit from Qiagen to remove the
background products.
2.6.1.2 Cloning of the ATP7B gene into pET-28 expression plasmids
The cloning of the ATP7B gene was designed such that the gene is inserted into the
respective pET28a(+) derived vectors with the NotI and BamHI recognition site. The
scheme for the ligation into these vectors is illustrated in the Figure 2.64

Figure 2.9 Organization used to clone the WDP gene into pET 28a (+) vectors.
Purified
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vector plasmids and the PCR products were digested with BamHI and NotI restriction
enzymes. The digestion reaction was incubated at 37oC for three hours and the vector
DNA purified by gel extraction using Qiagen gel extraction kit protocol and the digested
PCR insert DNA was product purified using Qiagen PCR purification kit. The purified
DNA samples were assessed by agarose gel electrophoresis to gauge purity and success
of the digestion (Figure 2.65).

Figure 2.10 (a) M; 1 kb DNA marker, 1 &2; PCR product for ATP7B. (b) M; 1kb DNA
marker; 1 &2 purified and digested PCR product, 3; purified and digested vector DNA.

2.6.1.3

Ligation reaction

The DNA insert was treated with T4 DNA ligase and incubated at room temperature for
20 min. The ligase was deactivated by incubating the reaction mixture at 70 °C for 10
min. The vector: insert ratio used for the ligation was 1:3. If 120 ng of vector DNA was
used, the amount of the insert DNA needed was calculated as follows:

!" $% &'()$* ∗ ,- ./0' $% /!.'*)
,- $% &'()$*
123!" ∗4.267 ,7.8,-

*

6
1

*

/!.'*)
&'()$*

= ng of insert

= 267.47 ng of insert
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2µL of the ligation reaction was then used to transform GigaSingles NovaBlue competent
cells and incubated overnight at 37°C. A single colony was inoculated into 5 mL LB
medium containing 50 µg/ml of kanamycin and grown at 37°C for 16 hours. The
plasmids were purified using Qiagen plasmid purification kit protocol. Restriction
mapping and agarose gel electrophoresis confirmed plasmids with inserts in the correct
orientation (Figure 2.67 C and D). DNA sequencing by Retrogen, Inc. (San Diego, CA)
further confirmed successful clones.

2.6.1.4 Induction test for the ATP7B protein expression
Plasmids containing full length ATP7B (minus the first 57 amino acids), were used to
transform Rosetta2(DE3) competent cells. Single colonies from an overnight growth
were used to inoculate 5 mL LB medium with kanamycin (5 µg/mL final concentration).
The culture was grown at 37°C with shaking and induced with IPTG (1mM final
concentration) at O.D 600 = 0.6 – 0.8. Protein expression was carried out for four hours at
37°C. Samples were taken hourly for four hours and protein expression assessed by SDS
gel electrophoresis. The expression of the full length ATP7B protein in Rosetta2(DE3)
cells was not evident in the absence of antibody detection. Lower molecular weight bands
appeared, but their origin needed to be verified by MALDI-TOF or Q-TOF mass
spectrometry (~ 40 kDa, Figure 2.67 C lanes 4-7).
Protein expression at lower temperatures, 16°C - 25°C was also attempted, but the
temperature reduction did not improve the yield. Different E. coli strains such as
BL21(DE3), C41(DE3), C41 pLysS, C43 and C43 pLysS were used for protein
expression. It was observed that when expression of the ATP7B protein was induced,
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most of the BL21(DE3) cells died. This was seen from a reduction in O.D.600 C41(DE3)
and C43(DE3), which are derivatives of BL21(DE3), are known to be effective in
expression of membrane proteins and toxic proteins,8,9 and were thus used for the
induction. Induction test with C41 and C43 cells at 18°C for 16 hours yielded a higher
molecular weight band of (~ 150 kDa, Figure 2.67 D lanes 3,4 and 7, 8 9 respectively).

Figure 2.11 Expression of ATP7B in Rosetta2 (DE3) cells (C) and C41 and C43
cells (D) lanes 3&4, and 7, 8, 9 respectively. A lower molecular weight

2.7

Summary

Wilson disease protein has been cloned into variants of pET28a(+) plasmids for the
expression in E. coli. Successful cloning was confirmed by DNA sequencing. Protein
expression at different temperature was attempted with different E. coli cell strains. C41
and C43 were able to express the protein at small scale and at 18°C. However, attempts
to scale up the expression were not successful. Future experiment may be designed in
such a way that either the ATP7B gene be synthesized to take advantage of codon
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optimization for the expression in E coli, alternatively different expression systems could
be used such as expression of the protein in mammalian cells or yeast.
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CHAPTER 3
BIOPHYSICAL PROPERTIES OF WD4-HAH1 CHIMERA

3.1 Introduction
Previous attempts to trap, and characterize the copper-bridged intermediate between WD4
and HAH1(Atox1) have not succeeded. Entropically linking these two protein together
may increase the residence time of the interaction or increase the number of bridged
intermediates within a given time frame. This can be assessed by a number of techniques
such as XANES/EXAFS, NMR, X-ray crystallography, gel filtration and light scattering.
The construction of the chimera utilized the native amino acids sequence that follows after
WD4, thus attempting not to perturb the native structure of the protein.

3.2 Construction of WD4-HAH1 expression plasmid
WD4-HAH1 is a chimera of two proteins (WD4 of ATP7B and HAHI, a copper chaperone
for ATP7B). The chimera was created by cloning HAHI at the C-terminal end of WD4
such that the two proteins are separated by a linker. This was achieved by creating a XmaI
site at the C-terminus of WD4 by mutating two amino acid residues (A432P and P433G)
of domain 5 of ATP7B. A plasmid in which domains four through six had been previously
cloned by Dr. Ibtesam Alja’afreh into a pET-32 Xa/LIC vector, here referred to as pET-32
Xa/LICWD4-6, was used. The HAH1 gene had previously been cloned into pET-11d
vector by Dr. David Huffman at Northwestern University.1 This plasmid was used as a
template for PCR amplification and HAH1 mutations. A mutation was made to remove
the XmaI site that is present in HAH1 gene and subsequently create a new XmaI site by
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mutagenesis when the gene was amplified by PCR. The PCR product was purified using
the QIAGEN PCR purification kit and the DNA was prepared for cloning by digestion with
the XmaI restriction enzyme. Both the purified vector (pET-32 Xa/LIC WD4-6) and
HAH1 PCR product were digested with the XmaI restriction enzyme by incubating at 37
o

C for 4 hrs. The vector DNA was dephosphorylated using Shrimp Alkaline Phosphatase

and purified by gel extraction (QIAGEN). The digested HAH1 DNA was purified using
QIAGEN PCR purification kit and its purity assessed using agarose gel electrophoresis
(Figure 2.69).

Figure 3.1 PCR product for HAH1 (210
bp) L; 1kb DNA marker, 1&2 HAH1
PCR product

HAH1 and the vector DNA containing WD4 were cloned using a molar ratio of 3:1 (insert:
vector) with T4 DNA ligase. The ligation reaction was performed at room temperature for
1 hour One tenth of the ligation reaction was used to transform NovaBlue competent cells.
Colonies were grown overnight at 37°C on LB plates with ampicillin (100 "g/mL final
concentration). Colonies were then screened for successful clones and the plasmid (pET32- WD4-HAH1) with the correct insert were confirmed by DNA sequencing. Figure 2.68
shows a flow diagram of cloning HAH1 into WD4.
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Figure 3.2 Flow diagram of WD4-HAH1 construct

3.3 Induction test for WD4-HAH1 protein expression
pET32-WD4-HAH1 plasmid was transformed into Rossetta2(DE3) competent cells for
small scale protein expression. Five colonies were screened for protein expression. Each
colony was inoculated in 5 mL LB with Ampicilin and incubated at 37°C (until O.D 600 =
0.6-0.8). Cells were then induced with 1 mM IPTG and incubated for an additional 4 hours
with shaking (250 rpm). Some samples were induced at 30℃ for 4-6 hrs. 300 µL of culture
was centrifuged to obtain pellet. The pellets were then prepared for SDS-PAGE (Figure
3.3).

Figure 3.3 Small scale protein expression at
30℃ for 4-6 hours. Lane M; protein marker,
Lane 1; 0 hours. induction, Lane 2; 1 hour.
induction, Lane 3; 2 hours. induction, Lane 4; 3
hours. induction, Lane 5; 5hours induction.

3.4 Protein expression and purification of WD4-HAH1

Rosetta2(DE3) competent cells were transformed with pET-32-WD4-HAH1 plasmid.
Colonies were grown to density at 37℃ in 5 mL LB/ampicillin. This starter culture was
then scaled up to 1 liter LB/ampicillin and incubated in a shaker at 37℃ until the O.D 600
= 0.6-0.8. Cells were then induced with 1mM IPTG and incubated for four hours with
shaking at 250 rpm. After four hours the cells were harvested by centrifugation at 4℃ for
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30 minutes at 15,000 rpm. The pellet was stored at -20oC. The pelleted bacteria were freezethawed in liquid nitrogen 5 times and re-suspended in phosphate lysis buffer at pH 7.4 (20
mM NaH2PO4, 100 mM NaCl, 2 mM MgCl2, 20 mM imidazole, 0.5 mM DTT). 1µL
Benzonase was added and re-suspended cells were mixed by gently shaking at 4oC for 30
minutes. The clarified supernatant was obtained centrifuging at 15000 rpm for 30 minutes
to obtain the supernatant.

3.5 His Trap purification of Trx-WD4-HAH1

The supernatant was filtered and loaded onto a HisTrap column (GE life science, 20 mL).
Prior to loading the sample, the column was washed with seven column volumes of elution
buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). The column was
equilibrated with seven column volumes of binding buffer (20 mM NaH2PO4, 500 mM
NaCl, 20 mM imidazole, pH 7.5) prior to loading the sample. The bound protein was eluted
by gradient elution with five column volumes of elution buffer (20 mM NaH2PO4, 500
mM NaCl, 500 mM imidazole, pH 7.5).

3.6 Gel filtration of Trx-WD4-HAH1

The protein was further purified using a HiLoad 26/60 Superdex 75 gel filtration column.
Fractions of HisTrap elution were combined, concentrated to 9 mL and loaded onto a gel
filtration column that had been pre-equilibrated with 2 column volumes of phosphate buffer
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(50 mM NaH2PO4, 200 mM NaCl, 10 mM DTT, pH 7.5). The protein sample was eluted
with 1.2 column volumes of the same buffer and purity of the protein was assessed using
SDS-PAGE (Figure 3.6). After gel filtration the protein was desalted with Tris-Cl ( 50 mM
Tris, 0.5 mM EDTA, 1 mM DTT, pH 8.0).

Figure 3.4.
SDS-PAGE for WD4~HAH1
Lane 1; pellet, lane 2; extract, lane 3-8;
His Trap elution fractions, lane 9; gel
filtration fraction, lane L; marker.

3.7 TRX-WD4-HAH1 digestion with TEV protease
WD4-HAH1 was expressed with a TEV-removable thioredoxin fusion tag. A TEV
protease cleavage site was inserted at the N-terminus of WD4 during cloning, and enables
the removal of the thioredoxin tag. The protein sample was then mixed with TEV at a mass
ratio of 80:1 (WD4-HAH1: TEV protease) and incubated for 12 hours at room temperature.
The TEV digested protein was then purified with HisTrap column to remove the fusion
tag. The digestion and the purity of the protein was assessed using SDS-PAGE (Figure3.7).
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Figure 3.5 Purification of WD4-HAH1. 1; Undigested Trx-WD4 Hah1 (with thioredoxin fusion
tag), 2 &3; Trx-WD4-HAH1 +TEV incubated for 6 hours and 12 hours respectively, 4 WD4HAH1 His trap fraction after TEV digestion, 5; pure WD4-HAH1after gel filtration, M; protein
marker.

3.8 Biophysical characterization of WD4-HAH
3.8.1 Introduction
Wilson disease protein (ATP7B) is a trans-membrane protein involved in cellular copper
metabolism. To date, the complete structure of the protein has not been solved. However,
structures of the individual domains have been elucidated. The N-terminal portion,
composed of 633 amino acid residues, has six soluble metal binding domains, that have a
ferredoxin-like fold and plays an important role in the copper acquisition. Each domain
also has a conserved GMT/HCXXC copper binding motif, and the two cysteine residues
coordinate the metal ion. The respective metal binding domains are separated by linkers.
Domains 1 and 2 are separated by 12 residues; domains 2 and 3 are separated by a 40
residue linker; domains 3 and 4 have a 30 residue while domain 4 and 5 are separated by a
56 residue linker; domain 5 and 6 have the shortest linker of 8 amino acids residues (Figure
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1.27). The structures of the metal binding domain of the ATP7B and the Menkes disease
protein have been solved by NMR and X-ray.2,3,4,5

Figure 3.6 Solution structure of WLN3-4 (PDB: 2ROP).

The interaction of the copper chaperone HAH1 with the metal binding domains has been
studied by solution NMR.6,7, 8 The six domains can receive copper from HAH1. Domain 6
can receive copper(I) from the chaperone without formation of an adduct. Domain 2 and 4
can simultaneously be loaded with copper(I) by the HAH1 chaperone with the formation
of copper dependent adducts.8 Isolated domain 5-6 can receive copper(I) from domain 4
but not from HAH1.3 This implies not all domains receive copper from or form adducts
with HAH1, but may receive the metal ion from other domains. Other species, such as
yeast and bacteria, have fewer domains.9 Banci et al. showed that a construct of WLN3-4
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was able to form a complex with Cu(I)HAH1. In the WLN3-4 construct, only domain 4
could form a stable adduct with Cu(I)HAH1 even though copper is efficiently transferred
to both the domains.2 A similar observation was made with the Menkes protein domain in
which both domain 3 and 4 were metallated by HAH1 with only domain 4 forming a stable
adduct.8 Domain 3 can be metallated by either Cu(I)HAH1 through weak interactions or
from metallated domain 4.2 The fact that not all domains form stable adducts with the
HAH1, implies that the domains have different surface characteristics, including their
interaction with the copper donor (HAH1 or other domains within the N-terminal portion
of the protein). It has been previously shown that domain four of ATP7B is the most stable
domain and that HAH1 may preferentially donate the copper(1) ion to this domain instead
of the other five domains. Even though HAH1 is known to form a stable adduct with
domain 4, the interactions between these two proteins has not been fully elucidated.

3.8.2

WD4-HAH1 chimera

The chaperone HAH1 has the same βαββαβ protein fold as the MBDs in ATP7B. The
transfer of Cu(I) to the MBD is dependent on the weak protein interactions between the
CXXC metal binding motifs of the two proteins. The MBDs location within the N-terminal
tail, electrostatic potentials and ability to orient in the correct direction may determine
complex formation with the chaperone HAH1. HAH1-MBD and MBD-MBD interactions
are very important in the function of the ATP7B; however, characterization of the transient
interactions has been challenging. Several methods have been used to investigate the
interaction of the chaperone HAH1 with the respective domains in ATP7A and ATP7B.
These include surface plasmon resonance,10 NMR,11,3,8 X-ray crystallography,1,12
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molecular dynamic (MD) simulations13,14 protein docking15 and single molecule
fluorescence resonance energy transfer (smFRET).16,17,18 Benitez et al. used smFRET
method to study the interaction of two proteins by encapsulating the chaperone HAH1 and
MBD4 of ATP7B in a nanovesicle both in the presence and absence of Cu(I). Their study
revealed that HAH1 interacts with MBD4 in two different geometries which can
interconvert dynamically.17 The multiple geometries may exist in order to increase the
probability of complex formation that leads to the copper transfer from the chaperone to
the metal binding domain. 17,19
Even though a number of studies have described the role of interactions in copper transfer
from the chaperone to the individual metal binding domains of ATP7B, no structure has
been reported for the complex formed between MBD4 and HAH1. In order to study the
complex of metal binding domain four of ATP7B and the HAH1 chaperone, the two
proteins were joined together to form a chimera referred to as WLN4-HAH1. The two
proteins are separated by a 55 residue linker that joins domain 4 and 5 in the native ATP7B
sequence.
3.8.3 WD4-HAH1 Mass spectrophotometry
The molecular weight of the WD4-HAH1 protein is 20.677 kDa as predicted using
ExPasy based on its protein sequence (Figure 3.7). SDS-PAGE results were consistent
with this mass. The exact molecular weight was verified by mass spectrophotometry,
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which revealed the molecular weight to be 20,687kD (Figure 3.83).

Figure 3.7 ESI-MS spectra for WD4-HAH1.

3.8.4

Circular dichroism of WD4-HAH1

The purified protein samples were buffer exchanged into 30 mM sodium phosphate, 150
mM NaCl, pH 7.5. Protein concentration was determined using the BCA assay. A 20 µM
protein concentration was used for CD measurements. The wavelength scan showed that
80

the # helix content of the protein is 28% (Figure 3.84). All measurements were done on a
JASCO J-815 CD Spectropolarimeter.
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Figure 3.8 CD spectrum for the
WLN4-HAH1. Alpha helical
content was determined to be 28%.
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3.8.5

Chemical unfolding of WD4-HAH1

Guanidine hydrochloride (GuHCl) was used for the chemical denaturation of WD4-HAH1.
The concentration of GuHCl was determined using the refractive index for accurate
concentration determination according to equation 3.
C = 57.147 (∆N) + 38.68 (∆N)2– 91.6(∆N)3

Eq. 3

Where C is the concentration of the GuHCl in moles/L and (∆N) = (refractive index of
solution minus refractive index of water). Protein samples were mixed with varying
concentrations of GuHCl (0 – 7.5 M) and incubated at room temperature for two hours.
The CD unfolding signal was followed at 222 nm. The CD data was fit in a three state
unfolding model using Origin®. The chimera protein unfolds with more than one transition
(Figure 3.85). The double sigmoidal curve corresponds to the unfolding of the HAH1 in
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the first transition followed by the unfolding of WD4 in the second transition. Table 3.8
summarizes the free energies of unfolding of WD4-HAH1 chimera.
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Figure 3.9 Chemical stability
measurements for WLN4-HAH1
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Table 3. 8. Free energy of unfolding of WD4-HAH1
1st transition
∆%&° ' (

mi

cm

(kJ/mol)

(kJ/mol)

(M)

1.05 ± 0.3

1.37 ± 0.02

6.11 ± 0.56

nd

2 transition
∆%&° ' (

mi

cm

(kJ/mol)

(kJ/mol)

(M)

44.8 ± 0 2.4

9.8 ± 1.2

5.61 ± 0.03

The free energy of unfolding for the first transition was found to be 6.1 ± 0.56 kJ/mol
while that of the second transition was 44.8 ± 0 2.4 kJ/mol. The GuHCl mid-point where
FD = FN for the first transition was determined to be 1.37 ± 0.02 M, and that of the second
transition was 5.61 ± 0.03 M.
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3.8.6 Thermal unfolding of WD4- HAH1
Thermal unfolding was followed at 222 nm and the temperature gradually increased from
25°C to 98 °C. It was determined that the chimera is very thermally stable and has a high

Molar Ellipticity * 10-6 (deg.cm2.dmol -1)

Tm about 78.1 ±0.3°C (Figure 3.86).

Figure 3.10 Thermal stability
measurements for WLN4HAH1. The protein was
determined to have a high
thermal stability with a melting
temperature of 78.1 ±0.3°C
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3.8.7 Crystallization of WD4-HAH1
Protein crystallization requires a supersaturated sample of protein. Crystals were obtained
using the hanging drop vapor-diffusion method with 1:1(v: v) protein (10 mg/mL) and
reservoir solution mixture at room temperature. In this method, a drop of a mixture of
protein and precipitant is sealed in a chamber with the precipitant.20 As the water
evaporates from the drop, vapor equilibrium is achieved between the protein and the
reservoir solution causing protein crystals to begin to form in a crystal nucleation zone.20
Initial screening was performed using the Hampton 96 well HR2-110 and HR2-112
screening kits to identify the buffer conditions that will yield protein crystals of WD4HAH1. Sparse matrix screening samples a broad range of buffers pre-selected from
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previously known conditions for producing protein crystals for X-ray diffraction studies.21
Sparse matrix screening facilitates the optimization of the buffer conditions, either by
changing its composition, or by altering the pH to improve the protein to crystallization
conditions. The HR2-110 crystal screen produced crystals with the buffer conditions of 0.2
M sodium citrate tribasic dihydrate, 0.1 M HEPES, NaCl, pH 7.5, 20% (v/v) 2-propanol
and 0.2 M zinc acetate dihydrate, 0.1 M sodium cacodylate trihydrate pH 6.5, 18% (w/v)
polyethylene glycol 8,000. Crystals were also obtained with the HR2-112 crystal screen
with buffer conditions of 0.1 M sodium chloride, 0.1 M BICINE pH 9.0, and 20% (v/v)
polyethylene glycol monomethyl ether 550. Protein crystals began to form after one week
and stopped growing in the second week (Figure 3.4 a and b). The crystals were confirmed
to be protein crystals by observing them under a UV microscope (Figure 3.87 c).

A

B

D

C

E

F

Figure 3.11 Protein crystals as viewed under optical microscope. (A) and (B) protein crystals
grown with Hamptons crystal screen HR2-110, (C) Crystals as seen under UV microscope, (D)
crystals growing on a horse hair, (E) crystals grown using seeds obtained with crystals grown
from horse hair, (F) single hexagonal protein crystal.
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Optimizing the primary conditions did not improve the quality of the protein crystals
obtained. This prompted the use of nucleating agents such as horse hair (Figure 3.4 d) and
microseeding techniques that are known to influence nucleation with considerable protein
crystallization success.22,23,24 Crystals from the initial screening were used as seeds to grow
new protein crystals (Figure 3.87 b), some of which grew in different buffer conditions
(0.5 M ammonium sulfate, 0.1 M MES monohydrate pH 6.5, 30% polyethylene glycol
monomethyl ether 5000). In order to eliminate false positives, the protein crystals were
visualized using a UV-light microscope to distinguish them from salt crystals. Proteins
with aromatic amino acids are intrinsically fluorescent when excited with UV light.
Tryptophan is more fluorescent than tyrosine and phenylalanine.25 When a crystal is
observed under visible light but not with UV illumination, it is likely a salt crystal.25
Crystals were transferred into a cryoprotectant that consisted of the reservoir solution plus
25% (v/v) glycerol and soaked for one minute. Crystals were looped, flash-frozen in liquid
nitrogen and sent for X-ray diffraction at the Advanced Photon Source, Argonne National
Laboratory, in collaboration with Dr. Amy Rosenzweig of Northwestern University. I
would like to especially thank Dr. Ingrid Span and Dr. Laura Dassama who helped mount
the crystals. The crystals failed to diffract and data couldn’t be collected for structural
determination but promising leads were identified.

85

3.9 Summary

This chapter covers the materials and methods used for the expression, purification and
preliminary crystallization of WD4-HAH1 chimera. The protein was able to crystalize at
room temperature with the optimum conditions of 0.5 M ammonium sulfate, 0.1 M MES
monohydrate pH 6.5, 30% polyethylene glycol monomethyl ether 5000, giving a single
hexagonal crystal (Figure 3.87 f). 25% glycerol was used as a cryoprotectant. Since
cryoprotecting crystals also requires optimization, future experiments could involve
screening different cryoprotectants or crystalizing the protein under different temperatures.
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CHAPTER 4
STRUCTURAL BIOINFORMATICS AND EXPERIMENTAL METHODS FOR
PfCuP-ATPASE
4.1 Introduction
PfCuP-ATPase gene (PF3D7_0904900) is located in chromosome 9 of the Plasmodium
falciparum genome. It has 7707 bp and encodes a 2568 amino acid protein with a predicted
molecular weight of 299390.12 Da. PfCuP-ATPase is the largest protein in the P-ATPase
family. The protein is homologous to the human copper ATPases: Menkes (ATP7A) and
Wilson disease (ATP7B) proteins. Unlike ATP7A and ATP7B, PfCuP-ATPase has
repeated inserts of 40-60 amino acids residues every 100-200 amino acids starting at
residue 600.1 The N-terminal region has only one copper binding motif (MTCDNC).
ATP7A and ATP7B have six metal binding domains with MXCXXC motifs and eight TM
domains, and CPC motif in the TM region which helps in the heavy metal transduction
across the membrane. TM domains were predicted using TMHMM, TopPred2 and TMpred
membrane prediction programs. Protein sequence alignment with M. musculus, H. sapiens
(ATP7B), S. aureus, P. yoelii, and P. chalaudi orthologues was done using ClustalW2.
PfCuP-ATPase, like other P-type ATPases, also has a DKTGT motif that is involved in
phosphorylation and a GDGINDCF motif that is involved in the binding of ATP. Between
the first and the second predicted TM domains, there is a predicted acidic domain with
repeats of 11 QDVKDD motifs (residue 1248-1361). These inserts are not present in other
known copper P-type ATPases.
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4.2 Structural prediction of PfCuP-ATPase
NCBI BLAST was used to search for sequence homology of the PfCuP-ATPase with the
known P-type ATPases. Sequence alignment was done using ClustalW2. ClustalW2 is
molecular biology program used for multiple protein sequence alignment.3 Alignment can
be across the entire sequence or only in certain regions.3 This makes it possible to identify
conserved regions of a sequence that may give information that helps in predicting the
function and structure of specific proteins.
Structured regions of the PfCuP-ATPase protein sequence were identified using Jpred3, a
protein secondary structure prediction server. It uses Jnet algorithms to identify the α-helix,
β-strand and coil regions in a protein sequence.4 Figure 4.0 shows a representative
secondary structure prediction of regions of the PfCuP-ATPase protein. The regions of
protein sequence that were predicted to contain secondary structures were used to predict
the tertiary structures using the Phyre2 server. Phyre2 is a tertiary structure prediction
program. Phyre2 is an online tool for the prediction of a potential three dimensional
structure of a protein based on the alignment to known protein structures in PDB.5 The
location and orientation of transmembrane helices PfCuP-ATPase were predicted using a
hidden Markov model (TMHMM).6, 7 The topology of PfCuP-ATPase was predicted with
TopPred2, an online server for the prediction of

hydrophobicity analysis topology

prediction of membrane proteins.8 The hydrophobicity plot (Figure 4.1) suggests that
PfCuP-ATPase has ten transmembrane domains.
The portion of the PfCuP-ATPase N-terminus to the first predicted transmembrane domain
is about 570 residues. Between the first and the second predicted transmembrane domains
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there is a long cytosolic loop (residues 590 - 1500, Figure 4.0). Within this loop there is a
predicted hypothetical acidic domain, (residues 1251-1510, Figure 4.3).

4.2.1 N-terminal domains of PfCuP-ATPase
Based on the aforementioned bioinformatics studies, the N-terminal 600 residues of
PfCuP-ATPase are predicted to have three structured domains. A long unfolded region
exists between domain 1 and domain 2. Domain two and 3 are in close proximity, with a
short linker between them. Only domain 2 has the MTCXXC copper binding motif. It was
predicted that PfCuP-ATPase has ten transmembrane domains (Figure 4.1). N-terminal
domains 2 and 3 are reminiscent of domains 5 and 6 of the Wilson disease protein. The
secondary structure of the hypothetical structured region in the N-terminal domain was
predicted using Jpred3, and the three-dimensional tertiary structure was predicted using
Phyre2 (Figure 4.0 and 4.2).

Figure 4.0 Protein sequence and secondary structure prediction by Jpred3 of domain 1 (residues 1 68), domains 2 (residues 390 - 474) and domain 3 (residues 480 – 561).
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4.2.2 Transmembrane prediction of PfCuP-ATPase

94
Figure 4.1 Hydrophobicity plot for the transmembrane prediction of PfCuP-ATPase. The transmembrane domains are shown in red bars

The first predicted N-terminal domain spans residues 1- 68 (here in referred to as PfCuPD1) based on secondary structure prediction using Jpred3 (Figure 3.1) and tertiary structure
prediction using phyre2 (Figure 4.2). Phyre2 predicted the hypothetical domain 1 to have
a ferredoxin fold with 82% confidence and 21% sequence identity with a heavy metal
binding domain of HMA7 (PDB: 3DXS), a copper P-type ATPase.9 PfCuP-D1 lacks the
metal binding motif.

Figure 4.2 Structural prediction of the of domain 1 of
PfCuP-ATPase. The domain is made of the first 68
residues of the N-terminal domain of PfCuP-ATPase.
The overall fold of the domain is !"!!"! which is
similar to the metal binding domain of ATP7B

The second predicted domain spans the residues 392 – 474 (Figure 4.0), is named PfCuPMBD2, and contains the metal binding motif MTCDNC. This domain is in close proximity
to the third hypothetical domain, PfCu-D3. Domain 3 is composed of residues 480 – 561
and lacks the metal binding motif. The predicted Domain 2 and Domain 3 are separated by
a short ten residue linker, and both are predicted to have a ferredoxin fold. They both
assume a ferredoxin fold (Figure 4.22). Their structural organization is reminiscent of
ATP7B domains 5 and 6 (PDB: 2EW9).10

Figure 4.3 PYMOL structure generated structure
from Phyre2 model of PfCuP-MBD2-3. Domain
2 is shown in purple while Domain 3 is colored
green. Domain 2 and 3 are separated by a ten
residue linker (colored red). Metal binding motif
of Domain 2 is shown in sticks.
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4.2.3 Beta barrel like domain with unknown function
A region of PfCuP-ATPase spanning from residue number 1248 to 1504 contains 11
repeats of the motif QDVKDD. This region is predicted to be structured and contains a
hypothetical domain with unknown function (Figure 4.23).

Figure 4.4 Hypothetical domain with a
QDVKDD motifs. The domain is
predicted to contain mostly beta sheets.

4.3 Plasmids construction, protein expression and purification of the N- terminal
domains of PfCuP-ATPase

This section describes the experimental methods for cloning, protein expression and
purification of N-terminal domains of PfCuP-ATPase.

4.3.1 PfCuP-D1 plasmid construction, protein expression and purification
The gene for the Plasmodium falciparum copper ATPase has a high percentage of A and
T nucleotides which makes expression in E. coli challenging.11 A gene construct containing
the sequence that encodes the predicted Domain 1 was synthesized by GeneScript, Inc.
Piscataway, New Jersey. Codon optimization was used to reduce the A and T content, and
keeping the expressed protein sequence unaltered. The synthesized gene was amplified by
PCR using KOD Hot Start DNA polymerase (Novagen). Mutagenic primers were designed
such that the forward primer introduces NcoI recognition site at the N-terminus of the
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PfCuP-D1gene while the anti-sense primer incorporates the BamHI site at the C-terminal
portion of the protein. The PCR reaction for the PfCuP-D1 was set up as detailed in Table
4.1

Table 4.1 PfCuP-D1 PCR reaction
Reagent

Volume
(µL)

Final
PCR Thermo cycler condition
concentration

5’-primer

1.5

0.3 µM

Step

Temperature(℃) Time(S)

3’-primer

1.5

0.3 µM

1. Polymerase
activation

95

300

2mM dNTPs

5

0.2 mM

2.
Deactivation

95

15

MgSO4

3

1.5 mM

3. Annealing

72

30

10X KOD
buffer

5

1X

4. Extension

72

6

Template for
PfCuP-D1

1

120 ng

Repeat steps
2-4 (30 times)

KOD Hot start
DNA
polymerase

1

0.02 U/μL

Hold

4

∞

Sterile water

32

Total volume

50

The PCR product for PfCuP-D1 (Figure 4.31 a) was purified using gel extraction kit from
Qiagen. Pure insert DNA and vector DNA were digested with the same restriction
endonucleases NcoI and BamHI in order to create the sticky ends that enable the ligation
of the gene insert into the pET24d(+) expression vector pET-24d(+). The digested insert is
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225 bp while the digested pET24d(+) vector is 5307 bp. The insert and vector DNA were
treated with T4 DNA ligase using the Quick Ligation Kit (BioLabs Inc.) and incubated at
room temperature for 20 min. The ligase was deactivated by incubating the reaction
mixture at 70°C for 10 min. The vector to insert ratio used for the ligation was 1: 3. 1 µL
of the ligation reaction was used to transform GigaSinglesTM NovaBlue competent cells
and colonies grown overnight at 37°C. A single colony was inoculated into 5 mL LB
containing 50 µg/mL of kanamycin and grown overnight at 37℃. Single colonies were
screened for the successful clones. The plasmids were purified using Qiagen plasmid
purification kit. The presence of the insert was confirmed by restriction mapping and
agarose gel electrophoresis (Figure 4.31 b and c).

Successful clones were further

confirmed by DNA sequencing at GeneScript USA Inc. Piscataway, New Jersey.

Figure 4.5PRC reaction and cloning of PfCuP-D1. (a)M; 1 kb DNA marker, 1; purified PfCuP-D1
PCR product. (b) Ligation of PfCuP-D1 into pET24d(+). M; DNA marker, 1; linearized
pET24d(+), 2-5; purified pET24d(+) with PfCuP-D1 insert DNA. (c) pET24d(+)-PfCuP-D1
plasmids were digested with NcoI and BamHI. M; DNA marker, 1-4; unsuccessful clones, 5 & 9;
plasmids with insert DNA, 6-8; plasmids that did not contain the insert DNA. Samples 5 &9 were
sequenced at GenScript USA Inc. to confirm the clones.
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4.3.2 Expression and purification of PfCuP-D1
PfCuP-D1 protein was expressed in E. coli. BL21(DE3) cells were transformed with the
pET24-PfCuP-D1 plasmid and colonies grown at 37°C for 16 hours. A single colony was
used to inoculate 5 mL of starter culture (LB media) containing 50 µg/ml Kanamycin
sulfate. This starter culture was grown to density in a 37°C shaker and inoculated into a 1
L culture. The culture was induced with a final concentration of 1mM IPTG (Isopropyl βD-1-thiogalactopyranoside) when the optical density at 600 nm reached 0.6-0.8. Protein
induction was carried out for 4 hours at 37°C, and cells were harvested by centrifugation.
Pelleted cells were re-suspended in a lysis buffer – 50 mM 2-(N-morpholino) ethane
sulfonic acid (MES), 150 mM sodium chloride, pH 6.5. The supernatant containing soluble
proteins was separated from cell debris by centrifugation. The supernatant was then filtered
using a 0.22 µm pore size hydrophilic membrane. The protein was purified in a two-step
process using cation exchange and size exclusion chromatography. The filtered supernatant
was loaded onto a cation exchange column pre-equilibrated with buffer A (50 mM MES
buffer, 150 mM NaCl, pH 6.5. The column was washed with three column volumes of
buffer A and the protein eluted using a gradient (Figure 4.32a) with buffer B (50 mM MES
buffer, 500 mM NaCl). Fractions containing PfCuP-MBD1 protein were pooled together
and concentrated using a 50 mL Amicon device fitted with a 3 kDa membrane. The protein
sample was then purified further by size exclusion chromatography, using a Superdex 75
High load 26/60 colmn (Figure 4.32b). The purity of the protein was assessed by SDSPAGE (Figure 4.33 a and b)
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Figure 4.8 (a). Protein expression of
PfCuP-MBD1 at 37 °C for 4 hours.
M; protein marker, 1; 4hrs
induction, 2; 3 hrs. induction, 3; 2
hrs. induction, 4;1-hour induction.
(b) 1; cation exchange fraction, 2;
gel filtration fraction.
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4.3.3 PfCuP-MBD2 and PfCuP-MBD2-3 plasmid construction
PfCuP-MBD2 is the second N-terminal domain of PfCuP-ATPase. It is the only domain
with the MXCXXC copper binding motif. The gene encoding PfCuP-MBD2 was amplified
from the synthesized gene PfCuP-MBD2-3 which was originally cloned into pUC57 by
GenScript, Inc. Difficulty of expression and solubilization led to the testing of multiple
constructs. These constructs are listed in Table 4.2.

Table 4.2 Expression plasmids for Domain 2 of Domain 2-3 of PfCuP-ATPase

Construct
pET24d+ PfCuP-MBD2

Description
Plasmid for PfCuP-MBD2 expression without a tag

pET24d+ PfCuP-MBD2-N

Plasmid for PfCuP-MBD2 expression with an Nterminal Histidine tag
Plasmid for PfCuP-MBD2 expression with a C-terminal
Histidine tag
Plasmid for PfCuP-MBD2 expression with a thioredoxin
fusion tag and a TEV protease site.

pET24d+ PfCuP-MBD2-C
pET32-TEV- PfCuP-MBD2
pET32-TEV- PfCuP-MBD2-G

pET32-TEV- PfCuP-MBD-⋁

pET32-TEV- PfCuP-MBD2-GT

Plasmid for PfCuP-MBD2 expression with a thioredoxin
fusion tag and a poly glycine tag after the TEV protease
site .
Plasmid for PfCuP-MBD2 expression with a thioredoxin
fusion tag and a TEV protease site with a Valine in the
second position.
Plasmid for PfCuP-MBD2 expression with a thioredoxin
fusion tag and a TEV protease site with a Threonine in
the second position.

pET24d+PfCuP-MBD2-∨ construct was made to express the PfCuP-MBD2 protein
without a purification tag, while pET24d+ PfCuP-MBD2-N and pET24d+ PfCuP-MBD2-
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C were designed such that the protein is expressed with a poly histidine tag at the N or C
terminus of the proteins, respectively. The PCR reaction for the amplification of PfCuPMBD2 and PfCuP-MBD2-3 genes was designed such that the forward primers introduce a
NcoI site at the N-terminal end of the gene while the reverse primer introduces a BamHI
recognition site at the C-terminal end. The PCR reaction and the thermocycle conditions
are outlined in Table 4.3.
Table 4.3 PCR reaction for PfCuP-MBD2 and PfCuP-MBD2-3
Reagent

Volume
(µL)

5’ primer

1.5

3’ primer

Final
Thermo cycler conditions
concentration
0.3 µM

Step

Temperature

Time

(ᵒC)

(S)

1.5

0.3 µM

1. Polymerase
activation

94

120

2mM dNTPs

5

0.2 mM

2. Deactivation

94

15

MgSO4

3

1.5 mM

3. Annealing

60

5

1X

4. Extension

72

30
5 s (for MBD2)

10X
buffer

KOD

11 s(for
MBD2-3)

Template for
PfCuPMBD2-3

1

120 ng

Repeat steps 24, 30 cycles

KOD Hot
start DNA
polymerase

1

(0.02 U/μL)

Hold

Sterile water

32.0

Total volume

50.0
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4

∞

The PCR reaction for the amplified PfCuP-MBD2 gene gave a product without side
reactions (Figure 4.34 a). The PfCuP-MBD2-3 PCR product was purified by gel extraction
kit from Qiagen to remove the unwanted products. The PfCuP-MBD2 PCR product was
purified using the Qiagen PCR purification kit protocol. The purified products and the
vector DNA were then digested with NcoI and BamHI enzymes and quantified using a
0.8% agarose gel. The PfCuP-MBD2 digested insert is 303 bp while the digested PfCuPMBD2-3 insert is 516 bp (Figure 4.9 a). Linearized pET24d (+) vector is 5263bp. 20 ng of
PfCuP-MBD2 and 35 ng of PfCuP-MBD2-3 of insert DNA were separately mixed with
120 ng of digested vector DNA and treated with T4 DNA ligase. The ligation mixture was
incubated at room temperature for 20 min. The ligase was deactivated by incubating the
reaction mixture at 70°C for 10 min.

Figure 4.9 PRC reaction and cloning of PfcuP-MBD2 and PfCuP-MBD2-3. (A) L, 1 kb DNA
marker, 1, 2, 3 PfCuP-MBD2 PCR product, lane 4, PfCuP-MBD2-3 PCR product. (B) Purified
cloned pET24d+ with the respective inserts. L; 1 kb DNA ladder,1-4; PfCuP-MBD2-3 construct,
5-9). (C) Linearized plasmids for PfCuP-MBD2-3 construct, 1-5 and PfCuP-MBD2, 6-9.

1 µL of the ligation reaction was then used to transform GigaSinglesTM NovaBlue
competent cells and incubated overnight at 37°C. A single colony was inoculated into 5
ml LB medium containing 50 µg/ml of kanamycin and grown overnight at 37°C. Single
colonies were screened for the successful clones. The plasmids were purified using Qiagen
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plasmid purification kit protocol (Figure 4.35 b and c ). Successful clones were further
confirmed by DNA sequencing at Retrogen, Inc. (San Diego, CA).

4.3.4 Protein expression and solubility of PfCuP-MBD2 and PfCuP-MBD2-3
PfMBD2 and PfMBD2-3 were expressed by transforming BL21(DE3) cells with the
expression plasmid pET24d-PfCuP-MBD2 and pET24d-PfCuP-MBD2-3, respectively.
Single colonies were used to inoculate into an LB culture with kanamycin sulfate (50
µg/mL final concentration). The culture was induced with a final concentration of 1mM
IPTG when the optical density at 600 nm reached 0.6-0.8. The proteins were expressed at
37°C for 3-4 hours and cells harvested by centrifugation. Initial extraction of the protein
either by a freeze thaw method or sonication was unsuccessful (Figures 4.10 and 4.11 ).

Figure 4.10 (a) PfCuP-MBD2 solubility screening, M; marker,1; extract 1 (freeze thaw), 2; extract 2
(sonication), post extract pellet, Figure 3.36 (b) PfCuP-MBD2 solubility screening, Pellet, extract 1
(freeze thaw), exract2(sonication), extract 3 (cation exchange), post extraction pellet, extraction with
1M urea, extraction with 3M urea, Marker

Figure 4.11 PfCuP-MBD2-3 protein expression and solubility screening. (a ) PfCuP-MBD2-3 protein
expressed at 37°C. M; Protein marker, 1; extract by freeze thaw, 2; extract by sonication, 3; pellet
before extraction, 4; pellet after extraction. (b) PfCuP-MBD2-3 protein expression at room temperature
(2-5hrs). (c)PfCuP-MBD2-3 protein extraction. M; marker, 1; pellet before extraction, 2; pellet after
extraction, 3; extract by sonication
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Both the proteins were formed inclusion bodies when induced at 37°C. Expressing the
proteins at a lower temperature (23-30°C) did not increase solubility (Figure 4.11 a, b and
c). Different lysis buffer conditions were screened. Extraction by sonication with 50 mM
Tris HCl, 150 mM NaCl, pH 8.5 increased the amount of protein in the soluble fraction but
not enough for characterization. The proteins were extracted under denaturing conditions
with a buffer containing 3M urea (Figure 4.10 b lane 6 and 7). These constructs were
abandoned and methods of expression of the protein as a fusion tag were explored. The
PfCuP-MBD2 and PfCuP-MBD2-3 were thus re-cloned into pET32Xa/LIC vector,
Novagen. The thioredoxin fusion tag is positioned at the N-terminal end of the protein of
interest. The tag will be removed by digesting the protein with TEV protease.

4.3.5 Construction of pET32-TEV- PfCuP-MBD2 and pET32-TEV- PfCuP-MBD2-3
plasmid
PfCuP-MBD2 was amplified from the pUC57-PfCuP-MBD2-3 plasmid which was
purchased from GeneScript, Inc. Amplification was done using the KOD Hot Start DNA
polymerase (Novagen) protocol (Table 4.4and 4.5). The forward primer was designed to
include the Tobacco Etch Virus (TEV) protease cleavage site before the start of the PfCuPMBD2 protein. Both sense and antisense primers contain A sequence compatible with the
Ligation Independent Cloning (LIC) cloning into the pETXa/LIC vector.

LIC is a

directional cloning method of the PCR product without the use of restriction enzymes or
ligation reactions.
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Table 4.4 KOD Hot Start DNA polymerase protocol (PfCuP-MBD2 amplification).
Reagent

Volume
Final
(µL)
concentration

PCR Thermo cycler condition
Temperature
(ᵒC)

Time(S)

0.3 µM

1. Polymerase
activation

95

300

5

0.2 mM

2. Deactivation

95

15

MgSO4

3

1.5 mM

3. Annealing

72

30

10X KOD
buffer

5

1X

4. Extension

72

5

Template for
PfCuP-D1

1

KOD Hot start
DNA
polymerase

1

4

∞

Sterile water

32.2

Total volume

50

5’ primer

1.4

3’ primer

1.4

2mM dNTPs

0.3 µM

Step

120 ng

Repeat steps 24, 30 cycles

(0.02 U/μL)

Hold
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Table 4.5 KOD Hot Start DNA polymerase protocol (PfCuP-MBD2-3 amplification).
Reagent

Volume
(µL)

Final
PCR Thermo cycler condition
concentration

5’ primer

1.4

0.3µM

3’ primer

1.4

0.3 µM

1. Polymerase
activation

94

120

2mM dNTPs

5

0.2 mM

2. Deactivation

94

15

MgSO4

3

1.5mM

3. Annealing

65

30

10X KOD buffer

5

1X

4. Extension

72

13

Template for
PfCuP-D1

1

120 ng

Repeat steps 24, 30 cycles

KOD Hot start
DNA
polymerase

1

(0.02 U/μL)

Hold

4

∞

Sterile water

32.2

Total volume

50

Step
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Temperature
(ᵒC)

Time
(S)

The PCR products corresponding to the PfCuP-MBD2 (334 bp) and PfCuP-MBD2-3 (545
bp) genes were purified using the PCR purification kit protocol (Qiagen) and quantified
using agarose gel electrophoresis (Figure 4.12 a and b ).

Figure 4.12 (A) Purified PCR product for PfCuP-MBD2 (334 bp) and (B) for
PfCuP-MBD2-3 (545 bp)

4.3.6 LIC cloning for PfCuP-MBD2 and PfCu-PMBD2-3
The insert DNA (0.2 pmol) was treated with T4 DNA polymerase as described in Table
4.37. The solution then was mixed and incubated at 22ºC for 30 min. The polymerase was
subsequently deactivated at 75ºC for 20 min. 2 µL of T4 DNA polymerase treated PCR
insert was then ligated into 1 µL of pET32Xa/LIC vector at 22ºC for 5 min. 1 µL of 25 mM
EDTA was added and incubated for a further 5 min at 22ºC. 1 µL of the ligation reaction
was used to transform GigaSinglesTM NovaBlue competent cells, cells were plated and
incubated overnight at 37ºC. Single colonies were used to inoculate 5 mL of LB with 50
µg/mL of kanamycin and incubated for 16 hours at 37ºC. Cells were harvested by
centrifugation and the plasmids were purified with the Qiagen plasmid DNA purification
kit (Figure 4.13 and 4.14. DNA sequencing at Retrogen, Inc. (San Diego) confirmed
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successful clones.
Table 4.6 T4 DNA polymerase protocol (treatment of PCR insert)
Reagent

Volume(µL)

0.2 pmol of insert DNA
10 X T4 DNA polymerase buffer

1
2

25 mM dGTP
100 mM DTT

2
1

T4 DNA polymerase

0.4

Nuclease free water
Total

13.6
20.0

Figure 4.13 Plasmid purification of
pET32XaLIC-PfCuP-MBD2

Figure 4.14 Plasmid purification of
pET32XaLIC-PfCuP-MBD2-3

4.3.7 Expression and purification of PfCuP-MBD2-Trx and PfCuP-MBD2-3-TRX
PfCuP-MBD2-Trx and PfCuP-MBD2-3-Trx (MBD2 and MBD2-3 with a thioredoxin
fusion tag) were expressed by transforming BL21(DE3) competent cells with pET32PfCuP-MBD2 and pET32-PfCuP-MBD2-3 plasmids, respectively. Single colonies were
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inoculated into 5 mL of LB starter culture with 100 µg/mL of ampicillin. When the culture
had grown to density it was scaled up to 1L. The culture was induced with 1mM IPTG
when the optical density at 600 nm attained 0.6 - 0.8. Proteins were expressed at 37ºC for
3 hours (Figure 3.39a) and the cells were harvested by centrifugation. Cells were resuspended in 50 mM sodium phosphate buffer, 150 mM NaCl, 0.5 mM DTT, pH 7.5. The
PfCuP-MBD2-Trx and PfCuP-MBD2-Trx proteins were extracted by sonication
(sonication time: 5 min, pulse 15 sec, hold 59 sec and amplitude 40%). The clarified
supernatant was obtained by centrifuging the lysate at 15000 rpm, for 20 min at 4ºC. The
supernatants containing the soluble proteins were filtered through a 0.22 µm pore size
membrane and loaded into a HisPrep FF 16/10 nickel column, which has a high affinity for
polyhistidine tagged proteins. The column was washed with three column volumes of 50
mM sodium phosphate buffer, 150 mM NaCl, 20 mM imidazole, pH 7.5. The protein was
eluted using a gradient 50 mM sodium phosphate, 150 mM NaCl, 300 mM imidazole, pH
7.5. The eluted protein was buffer exchanged on a PD10 desalting column with a TEV
cleavage buffer (50 mM Tris/HCl, pH 8.0). To remove the thioredoxin fusion tag, TEV
protease was added to the desalted protein (1: 80 mass ratio) and incubated overnight at
room temperature. The degree of TEV cleavage was assessed by SDS-PAGE (Figure 4.16
and 4.17).

4.3.8 Inclusion of a fusion tag increased solubility but reduced the TEV protease
activity
The attachment of the fusion tag to the PfCuPMBD2 protein increased the solubility of the
proteins (Figure 4.39 b). However, it was extremely challenging to remove the fusion tag
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using the protease. The final protein sample obtained was not usable for any
characterization as much of the protein retained the tag (Figure 4.17)

Figure 4.15. 12.5% SDS-PAGE gel showing the
expression of PfCuP-MBD2Trx and PfCuPMBD2-3Trx

Figure 4.16. 12.5% SDS-PAGE showing
purification of PfCuP-MBD2. TEV protease
was not able to cut the fusion tag.

Figure 4.17. 12.5 % SDS-PAGE gel showing the steps for
the purification of PfCuP-MBD2. Digestion with TEV
protease was not successful. Only about ten percent of the
protein was obtained upon tag removal. The activity was
at minimal. Optimizing the digestion conditions like
temperature, buffer and salt conditions did not increase
the activity of the protease

4.3.9 Addition of polygycine (six glycine residues) at position 2 of TEV protease
recognition site.
Different residues were added at position 2 (P2) after the TEV protease cut site. Addition
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of polygycine residues at this position was expected to expose the protease cleavage site
making it more accessible to the enzyme. Other residues were inserted into other constructs
(two glycine, two valine and two threonine residues) by site directed directed mutagenesis.
All these efforts proved unsuccessful (Figure 4.18).

Figure 4.18. Activity of TEV protease on
MBD2 Introducing an extra residue or poly
glycine at position two did not change the
TEV protease efficiency.

4.4.0 PfCuP-MBD2-C and PfCuP-MBD2-3 C-terminal poly histidine tag
PfCuP-MBD2 and PfCuP-MBD2-3 were recloned into a pET24d(+) vector that places the
TEV protease site and a polyhistidine tag (HHHHHH) at the C-terminal end of PfCuPMBD2 (shown in red in Figure 4.41 (b)) and PfCuP-MBD2-3.

Figure 4.19 TEV protease cut site at the Nterminal portion of PfCuP-MBD2. This cut site is
relatively buried
between domain 2 (in
magenta) and 3 (in green). It is possible that the
loop between beta sheet 2 and alpha helix 2 in
domain 2(shown in yellow) could be hindering
the TEV protease from accessing the cut site.
New TEV protease site introduced at the Cterminus of domain 2 and domain 3 respectively.

The new constructs were named pET24d-PfCuP-MBD2-C and pET24d-PfCuP-MBD2-3C. A general procedure for the PCR reaction and cloning was followed, as described
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previously. Successful clones were confirmed by DNA sequencing.

4.4.1 Expression and purification of PfCuP-MBD2-C and PfCuP-MBD2-3 C-terminal
poly histidine tagged proteins
Protein expression was performed at room temperature and at 18°C. The solubility was the
highest when the proteins were expressed 18°C. Purification was performed using
immobilized nickel ion affinity chromatography (Figure 4.20).
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Figure 4.20 His Trap purification of
PfCuP-MBD2 and PfCuP-MBD2-3

Figure 4.21 SDS gel for Purification of PfCuPMBD2. M; protein marker, 1; HisTrap sample,
2; MBD2 with TEV protease, 3; MBD2 after
TEV protease digestion
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Figure 4.23 SDS gel for Purification of PfCuPMBD2-3. M; protein marker, 1-3; HisTrap
sample, 4-5; MBD2-3 with TEV protease, 6; pure
MBD2-3 after TEV protease digestion

Figure 4.22 Gel filtration
Purification of PfCuP-MBD2
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The histidine tag was removed by digesting the protein with the TEV protease at a mass
ratio of 1:80 overnight at room temperature. Pure protein without the affinity tag was
collected as a flow through, concentrated and purified further by gel filtration (Figure 4.22).
Purity of the protein sample was assessed by SDS-PAGE (Figure 4.21 and 4.23)

4.5.0 PfCuP-D3 construct
N-terminal Domain 3 is closest to the first transmembrane domain in the PfCuP-ATPase.
This hypothetical domain lacks the copper binding motif of copper ATPases. The gene
sequence spanning this region of the protein was amplified by PCR from the GeneScript
Inc. synthesized pUC57-PfCuP-MBD2-3 plasmid. The PfCuP-MBD3 construct amplified
did not incorporate the fusion fusion or affinity tags. The forward primer and the reverse
primers incorporated NcoI and BamHI cut sites, respectively. The PCR conditions are as
outlined in Table 4.7.
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Table 4.7 KOD Hot Start DNA polymerase protocol for PfCuP-D3 amplification

Reagent

Volume
(µL)

Final
Thermo cycler conditions
concentration

5’ primer

1.5

0.3 µM

3’ primer

1.5

0.3 µM

2mM dNTPs

5.0

MgSO4

Temperature
(°C)

Time(S)

1. Polymerase
activation

94

300

0.2 mM

2. Deactivation

94

15

3.0

1.5mM

3. Annealing

65

30

KOD

5.0

1X

4. Extension

72

30

Template for
PfCuP-MBD23

1.0

120 ng

Repeat steps 24 (30 cycles)

KOD Hot start
DNA
polymerase

1.0

(0.02 U/μL)

Hold

4

∞

Sterile water

32.0

Total volume

50.0

10X
buffer

Step
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The PCR product was purified using the Qiagen gel extraction kit protocol and digested
with NcoI and BamHI restriction endonucleases. Cloning of the PfCuP-MBD3 into
pET24d+ vector was carried out as previously described in the cloning of PfCuP-D1.

Figure 4.24 PfCuP-D3 PCR reaction
and cloning. (a) M, DNA marker, 1;
digested pET24d(+), 2; digested PfCuPD3 PCR product. (b) M; DNA marker,
1&2; unsuccessful clones, 3-5; cloned
plasmids with PfCuP-D3 insert.

4.5.1 Expression and purification of PfCuP-D3
The expression plasmid for PfCuP-D3 was used to transform BL21 (DE3) competent cells,
which were plated overnight at 37°C . A single colony was used to inoculate LB culture
with kanamycin sulfate (50µg/ml final concentration) and grown at 37°C. The culture was
induced with a final concentration of 1mM IPTG when the optical density at 600 nm
reached 0.6-0.8. The proteins were expressed at 37°C for 3 hours and cells harvested by
centrifugation. Pelleted cells were re-suspended in lysis buffer: 50 mM sodium phosphate,
150 mM NaCl, 1 mM DTT, pH 7.5. The suspension was sonicated (for 5 min, 15 sec pulse,
59 sec hold, and 40% amplitude) and centrifuged for 20 min at 4°C. The supernatant was
filtered and loaded onto a anion exchange column (DEAE sepharose) pre-equilibrated with
lysis buffer. The column was washed with three column volumes of the same buffer and
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protein was eluted using a gradient with 50 mM sodium phosphate buffer, 1 mM DTT, 500
mM NaCl, pH 7.5 (Figure 4.25). Fractions containing the protein were combined together
and purified further using a size exclusion chromatography column, Highload Superdex 75
16/60 (Figure 4.26). Fractions containing pure protein were combine together,
concentrated and the purity assessed by SDS-PAGE (Figure 4.27).
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Figure 4.25 Anion exchange
purification of PfCuP-D3
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Figure 4.26 Size exclusion
chromatography for PfCuP-D3.
The protein purifies both as a
monomer and a dimer
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Figure 4.27 Purification steps for PfCuP-MBD3.
1=marker, 2= pellet, 3= extract, 4= purification by
anion exchange, 5=, gel filtration purification
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4.6 Biophysical methods used for characterization of N-terminal domains of PfCuPATPase
4.6.1

Circular Dichroism (CD)

CD spectroscopy is used to study chiral molecules of all sizes, and has many applications
in biomolecular studies. Its primary use is the determination of relative amounts of
secondary structure, and the overall conformation of the macromolecule. The technique is
useful in folding and binding properties of proteins.12 Secondary structure of biological
molecules such as proteins can be effected by pH and temperature. CD can be used to study
the structural changes in macromolecules due to changes in environmental conditions, the
interactions with other molecules, and kinetic and thermodynamic properties.
CD spectroscopy is measured in the both visible and ultraviolet region of the
electromagnetic spectrum. The CD signal can be positive or negative. If the left-handed
circularly polarized light (L-CPL) is absorbed to a greater extent than the right-handed
circularly polarized light (R-CPL) the signal will be positive. The signal will be negative
if the L-CPL is absorbed at a lesser extent than the R-CPL.

4.6.2 CD measurements units and conversions
Circular dichroism is measured as the differential absorbance of the L-CPL and R-CPL. It
is expressed as:
CD= ΔA(λ) = A(λ)L-CP – A(λ)R-CPL

Eq. 4.3

where λ is the wavelength.
Molar circular dichroism
Δϵ = ϵLCPL - ϵRCP =

'(
)∗+
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Eq. 4.4

Where C is concentration in moles/L and , is the path length in cm
Mean residue molar circular dichroism (ΔϵMR)
Mean residue molar circular dichroism is a unit that is specific for protein. It measures the
molar CD for individual residues instead of the entire protein.
01

ΔϵMR =

Eq. 4.5

)23∗+

CMR (mean residue concentration) = C*N
N = number of the amino acids in the protein.
If the sequence of the protein is not known, CMR can be calculated using average amino
acid weight of 113 Daltons.
CMR =

4

Eq. 4.6

556

Degrees of ellipticity (ϴ)
When linearly polarized light is passed through a chiral sample it will be elliptically
polarized i.e. light that is not fully circular polarized (light that is elliptical in shape).
ΔA =

7

Eq. 4.7

68.:;8

[ϴ] is expressed in degrees cm2dmol-1 or in degrees M-1m-1
M-1m-1 =

5<<<=>?
>@+.5<<.=>

=

5<.=>A
>@+

[ϴ] =
Δϵ =

[ϴ]
68:;.8

= BC8 DCE, F5
5<<∗ ϴ

Eq. 4.8

)∗+

the factor is 100 fold larger than the absorbance since the path length for

ellipticity if defined in meters.
Mean residue ellipticity ([ϴ]MR)
[ϴ]MR is the molar ellipticity of individual residues in a protein.
[ϴ]MR =

5<<∗7

Eq. 4.9

)23∗+
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4.7 Circular Dichroism of biological molecules
19 out of the 20 amino acids found in proteins are chiral, as are the nucleic acids, DNA and
RNA. Therefore, CD is an important tool for studying these biological molecules. The CD
spectra of proteins and nucleic acids is influenced by the three dimensional structure of the
macromolecule.

4.7.1 Protein circular dichroism
The CD spectra in the far-UV can be used to predict the percentage of each of secondary
structural element in a protein, making it an important method to evaluate the secondary
structure, folding, binding properties and functional properties of proteins. When the
amide chromophores of a polypeptide backbone of a protein are aligned in arrays, the
optical transitions reflect multiple transitions resulting in a characteristic CD spectrum that
represents the structural elements of the macromolecule. The most studied circular
dichroism signatures are the secondary structures of proteins α-helices, β-sheets and
random coil. These secondary structures have particular signatures in the circular
dichroism spectrum. α-helical proteins have negative bands at 222 nm and 208 nm and a
positive band at 193 nm13, β-strands have a negative band at 218 nm and a positive band
at 195 nm, the random coil (disordered proteins ) have very low ellipticity above 210 nm
and negative bands near 195 nm14(Figure 4.7). In the near-UV region of the spectra (250350 nm) the chromophores used for the CD signal are aromatic amino acids and the
disulfide bonds of cysteine. Tyrosine gives a signal between 270-290 nm, phenylalanine at
250-270 nm and tryptophan residues at 280-300 nm. Disulfide bonds gives a broad weak
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signal that is spread throughout the entire-UV region. Well defined signals in the near UVregion is indicative of a well folded protein. 15, 16

Figure 4.28 Far-UV CD spectrum for different
secondary structure of protein.2

4.7.2

Nuclear magnetic resonance (NMR) spectroscopy

Understanding the relationship between structure and function of proteins, especially in
mordern biology, is to determine the three dimensional protein structure. Nuclear magnetic
resonance (NMR) spectroscopy is a unique technique that can be used to determine the
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protein structure and investigate protein-protein interactions.17,18,19,20,21 An advantage of
NMR spectroscopy is that the molecules are free in solution, and not restrained by
unnatural parking forces. This is particularly important for proteins or complexes that are
not easy to crystallize because regions of the protein are conformationally dynamic. The
proteins studied are either singly or doubly isotopically labelled with 13C and 15N. This is
achieved by expressing the protein in minimal media supplemented with labeled carbon
and nitrogen sources.
To isotopically label samples, protein expression plasmids were transformed into
BL21(DE3) cells and colonies were grown at 37℃ overnight on LB/agar plates containing
Kanamycin. One colony was used to inoculate a 5 mL starter culture of LB media, which
was grown overnight at 37℃ with shaking at 250 rpm. 500 µl of the starter culture was
then used to inoculate 500 mL of minimal media and protein expression was induced by
adding 1 mM IPTG when O. D600 = 0.6. PfCuP-D1 and PfCuP-D3 were expressed for four
hours at 37℃ while PfCuP-D2 and PfCuP-D2-3 were expressed at room temperature for
six hours. 1 L of minimal media contained 42 mM Na2HPO4, 22 mM of KH2PO4, 10 mM
NaCl, 11 mM

13

C glucose, 18 mM

15

N NH4Cl, 1 mM MgSO4, 0.02 mM CaCl2, 1 Ig

thiamine and 50 µg/ml of kanamycin. Protein purification was carried according to the the
protocol in Section 4.3.2, 4.4.1and 4.5.1
The concentration of proteins in the NMR samples ranged between 300 µM- 600 µM. The
optimal solution for NMT studies contained 30 mM sodium phosphate buffer (pH 7.5), 150
mM NaCl and 1 mM DTT. All experiments were performed at 25℃. All chemical shifts
were referenced to a 100 µM of sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS)
standard was used to reference the chemical shifts. A summary of the experiments that
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were run on various constructs of PfCuP-ATPase are shown in Table 4.8

Table 4.8 Solution NMR experiments performed on the protein constructs
Protein
construct

Experiment

Comment

PfCuP-D1

1

H-15N HSQC

Shows all H-N correlations

PfCuP-MBD2

1

H-15N HSQC

Shows all H-N correlations

PfCuP-D3

1

H-15N HSQC

Shws all H-N correlations

HNCACB

Correlates the chemical shift of an amide proton
to the Cα and Cβ of the same residue and those
of the preceding residue.

HNCA

Correlates the chemical shift of amide proton of
a residue the Cα of the same residue as well as
the Cα of the preceding residue. Magnetization
is transferred from the amide proton to 13Cα via
the N-Cα J-coupling and back to 15N and 1H
hydrogen for detection. 22, 23

CBCA(CO)NH

Magnetization is transferred from 1Hα and 1Hβ
to 13Cα and 13Cβ, respectively, and then from
13
Cβ to 13Cα. It is then transferred first to13CO,
then to 15NH and then to 1HN for detection.24

HN(CO)CA

Often used together with HNCA. It correlates
the resonances of the amide proton of a residue
with the Cα of the preceding residue.

HNCO

Correlates between the 15N-1H pair of one
residue with the carbonyl (13CO) resonance of
the preceding residue
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Table 4.72 –Continued
Magnetization
exchanged

NOESY

between

is
all

hydrogen atoms within 5Å
then

transferred

to

neighboring 15N nuclei and
back to 1H for detection.25,

4.7.3

PfCuP-D3 backbone assignments

Backbone resonance assignments for PfCuP-D3 were obtained by using the 1H-15N HSQC,
CBCANH and CBCA(CO)NH spectra. The general approach involves the walking the
protein backbone and sequentially making chemical shifts assignments using pairs of
experiments. For example, the HNCACB shows correlations between N(i), H-N(i) with Cα
and Cβ of i and i-1, while the CBCA(CO)NH spectra shows correlations between N(i), HN(i) and the Cα and Cβ atoms of i-1. Using 1H,15N HSQC spectra, a single peak was
randomly selected and named i. The same peak was then identified in the 3D experiments,
and the 1H, 13C planes revealed the associated 13C chemical shifts. The HNCBCA shows
carbon resonances, corresponding to the Cα and Cβ from i-1, and ii residues. Assignment
of the four resonances to the i-1 or I residue was achieved by using CBCA(CO)NH which
only shows correlations to the Cα and Cβ from i-1 and i. The two resonances that appear
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in the HNCACB experiment, but not in the CBCA(CO)NH experiments are assigned to
residue i. The 13C chemical shifts of residue I were compared to those of all resonances in
the CBCA(CO)NH experiment to identify the N and H chemical shift of the next residue
(i+i) in the protein sequence. These steps were sequentially repeated to ‘walk’ along the
backbone of the amino acid sequence, and connecting the assignments for residues i-1, i,
i+1, i+2, i+3….i+n. Ascribing the sequentially connected assignments to specific amino
acids in the protein sequence makes use of the unique spectral properties of certain amino
acids. Serine and Threonine, for instance, have Cβ resonances at higher ppm values
(downfield) than Cα resonances. Also, Glycine only has a Cα atom, alanine has a Cβ
resonance at a low ppm (upfield), and Proline lacks a backbone NH resonance. Figure 4.29
shows representative strip plots from residues 506 to 512.

Figure 4.29 Backbone assignment between residues 506 – 512. The arrows show the
connection of the peaks during the ‘walk’ through in assignments steps.
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4.7.4

Determination of the CuI binding affinities

Experiments to determine the copper binding affinities of PfCuP-MBD2, PfCuP-MBD2-3,
DdCuP-MBD1 and DdAtox1 were performed in an anaerobic glove box (NEXXUS
chamber in N2 atmosphere) by reacting apoprotein with CuM [(BCS)8 ]6F in deoxygenated
buffers. The proteins were reduced excess DTT (≥10 mM DTT) in the glove box, and then
the buffer was exchanged into 30 mM sodium phosphate, 150 mM NaCl, pH 7.5, using a
PD10 desalting column. The buffer solutions were made fresh and degassed before use.
The protein was concentrated using Amicon device with a 3 kDa membrane and the protein
concentration was determined using a BCA assay. The copper ligand complex
CuM [(BCS)8 ]6F was formed by mixing CuM in the form of tetrakis(acetonitrile)copper(I)
hexafluorophophate [(CH6 CN)T Cu]UVW with Bathocuproinedisulfonic acid (BCS) at a ratio
of 1:2.5 to ensure formation of the 1:2 complex,

[ CuM (BCS8 )]6F , with negligible

contribution of the 1:1 complex, CuM (BCS)]F .26 The BCS affinity for copper(I) is
comparable to that of protein thiols at subfemtomolar concentrations. It reacts with Cu(I)
in 1:2 to form a stable complex anion [ CuM (BCS)8 ]6F with a maximum absorption at 483
nm.27 A series of reactions were prepared by increasing the apoprotein concentration by
titrating it into the complex ligand. The solutions were adjusted with the reaction buffer to
a fixed volume so as to keep the concertation of (CuM (BCS)8 6F constant, and only the
concentration of protein in all the solutions was varied. The apoproteins were titrated
against two different with different concentration of [CuM (BCS)8 ]6F complex, with at least
two independent replicates. Copper affinity binding constants was measured using the
transfer of CuM independent replicates. The copper binding affinities was measured using
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the transfer of CuM from the [CuM (BCS)8 ]6F to the protein as established by the change in
absorbance for [CuM [ BCS 8 ]6F at 483 nm.

127

4.8 REFERENCES

1.

Rasoloson, D.; Shi, L.; Chong, C. R.; Kafsack, B. F.; Sullivan, D. J., Copper
pathways in Plasmodium falciparum infected erythrocytes indicate an efflux role
for the copper P-ATPase. Biochem J 2004, 381 (Pt 3), 803-11.

2.

Martin, S. R.; Schilstra, M. J., Circular dichroism and its application to the study
of biomolecules. Methods Cell Biol 2008, 84, 263-93.

3.

Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T. J.; Higgins, D. G.;
Thompson, J. D., Multiple sequence alignment with the Clustal series of
programs. Nucleic Acids Res 2003, 31 (13), 3497-500.

4.

Cole, C.; Barber, J. D.; Barton, G. J., The Jpred 3 secondary structure prediction
server. Nucleic Acids Res 2008, 36 (Web Server issue), W197-201.

5.

Kelley, L. A.; Mezulis, S.; Yates, C. M.; Wass, M. N.; Sternberg, M. J., The
Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015,
10 (6), 845-58.

6.

Sonnhammer, E. L.; von Heijne, G.; Krogh, A., A hidden Markov model for
predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst
Mol Biol 1998, 6, 175-82.

7.

Krogh, A.; Larsson, B.; von Heijne, G.; Sonnhammer, E. L., Predicting
transmembrane protein topology with a hidden Markov model: application to
complete genomes. J Mol Biol 2001, 305 (3), 567-80.

8.

von Heijne, G., Membrane protein structure prediction. Hydrophobicity analysis
and the positive-inside rule. J Mol Biol 1992, 225 (2), 487-94.

128

9.

Zimmermann, M.; Clarke, O.; Gulbis, J. M.; Keizer, D. W.; Jarvis, R. S.; Cobbett,
C. S.; Hinds, M. G.; Xiao, Z.; Wedd, A. G., Metal binding affinities of
Arabidopsis zinc and copper transporters: selectivities match the relative, but not
the absolute, affinities of their amino-terminal domains. Biochemistry 2009, 48
(49), 11640-54.

10.

Achila, D.; Banci, L.; Bertini, I.; Bunce, J.; Ciofi-Baffoni, S.; Huffman, D. L.,
Structure of human Wilson protein domains 5 and 6 and their interplay with
domain 4 and the copper chaperone HAH1 in copper uptake. Proc Natl Acad Sci
U S A 2006, 103 (15), 5729-34.

11.

Vedadi, M.; Lew, J.; Artz, J.; Amani, M.; Zhao, Y.; Dong, A.; Wasney, G. A.;
Gao, M.; Hills, T.; Brokx, S.; Qiu, W.; Sharma, S.; Diassiti, A.; Alam, Z.;
Melone, M.; Mulichak, A.; Wernimont, A.; Bray, J.; Loppnau, P.; Plotnikova, O.;
Newberry, K.; Sundararajan, E.; Houston, S.; Walker, J.; Tempel, W.; Bochkarev,
A.; Kozieradzki, I.; Edwards, A.; Arrowsmith, C.; Roos, D.; Kain, K.; Hui, R.,
Genome-scale protein expression and structural biology of Plasmodium
falciparum and related Apicomplexan organisms. Mol Biochem Parasitol 2007,
151 (1), 100-10.

12.

Greenfield, N. J., Using circular dichroism collected as a function of temperature
to determine the thermodynamics of protein unfolding and binding interactions.
Nat Protoc 2006, 1 (6), 2527-35.

13.

Holzwarth, G.; Doty, P., The Ultraviolet Circular Dichroism of Polypeptides. J
Am Chem Soc 1965, 87, 218-28.

129

14.

Venyaminov, S.; Baikalov, I. A.; Shen, Z. M.; Wu, C. S.; Yang, J. T., Circular
dichroic analysis of denatured proteins: inclusion of denatured proteins in the
reference set. Anal Biochem 1993, 214 (1), 17-24.

15.

Kelly, S. M.; Jess, T. J.; Price, N. C., How to study proteins by circular dichroism.
Bba-Proteins Proteom 2005, 1751 (2), 119-139.

16.

Greenfield, N. J., Using circular dichroism spectra to estimate protein secondary
structure. Nat Protoc 2006, 1 (6), 2876-90.

17.

Akhmedov, M.; Catay, B.; Apaydin, M. S., Automating unambiguous NOE data
usage in NVR for NMR protein structure-based assignments. J Bioinform Comput
Biol 2015, 13 (6), 1550020.

18.

Joo, K.; Joung, I.; Lee, J.; Lee, J.; Lee, W.; Brooks, B.; Lee, S. J.; Lee, J., Protein
structure determination by conformational space annealing using NMR geometric
restraints. Proteins 2015, 83 (12), 2251-62.

19.

Bonvin, A. M.; Boelens, R.; Kaptein, R., NMR analysis of protein interactions.
Curr Opin Chem Biol 2005, 9 (5), 501-8.

20.

Takeuchi, K.; Wagner, G., NMR studies of protein interactions. Curr Opin Struct
Biol 2006, 16 (1), 109-17.

21.

O'Connell, M. R.; Gamsjaeger, R.; Mackay, J. P., The structural analysis of
protein-protein interactions by NMR spectroscopy. Proteomics 2009, 9 (23),
5224-32.

22.

Kay, L. E.; Ikura, M.; Tschudin, R.; Bax, A., Three-dimensional triple-resonance
NMR Spectroscopy of isotopically enriched proteins. 1990. J Magn Reson 2011,
213 (2), 423-41.

130

23.

Farmer, B. T., 2nd; Venters, R. A.; Spicer, L. D.; Wittekind, M. G.; Muller, L., A
refocused and optimized HNCA: increased sensitivity and resolution in large
macromolecules. J Biomol NMR 1992, 2 (2), 195-202.

24.

Grzesiek, S.; Dobeli, H.; Gentz, R.; Garotta, G.; Labhardt, A. M.; Bax, A., 1H,
13C, and 15N NMR backbone assignments and secondary structure of human
interferon-gamma. Biochemistry 1992, 31 (35), 8180-90.

25.

Marion, D.; Driscoll, P. C.; Kay, L. E.; Wingfield, P. T.; Bax, A.; Gronenborn, A.
M.; Clore, G. M., Overcoming the overlap problem in the assignment of 1H NMR
spectra of larger proteins by use of three-dimensional heteronuclear 1H-15N
Hartmann-Hahn-multiple quantum coherence and nuclear Overhauser-multiple
quantum coherence spectroscopy: application to interleukin 1 beta. Biochemistry
1989, 28 (15), 6150-6.

26.

Xiao, Z.; Brose, J.; Schimo, S.; Ackland, S. M.; La Fontaine, S.; Wedd, A. G.,
Unification of the copper(I) binding affinities of the metallo-chaperones Atx1,
Atox1, and related proteins: detection probes and affinity standards. J Biol Chem
2011, 286 (13), 11047-55.

27.

Xiao, Z.; Donnelly, P. S.; Zimmermann, M.; Wedd, A. G., Transfer of copper
between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins.
insights into mechanisms of copper uptake and hypoxia selectivity. Inorg Chem
2008, 47 (10), 4338-47.

131

CHAPTER 5
BIOPHYSICAL PROPERTIES OF THE N-TERMINAL DOMAINS OF PfCuPATPase: PfCuP-D1, PfCuP-MBD2, PfCuP-MBD2-3 and PfCuP-D3

5.1 Introduction
Understanding the physical properties of the N-terminal domains of PfCuP-ATPase will
help elucidate the copper transport mechanism of the protein. The N-terminal region is
about 564 amino acid residues in length, yet it has only one copper binding domain. The
two additional domains lacking the metal binding motifs had not been previously
identified. These domains are connected with a linker of varying lengths. Domain 1 is
linked to domain 2 with approximately 321 residues while Domain 2 is linked to Domain
3 by a ten residue linker. PfCuP-D1 is the first predicted N-terminal domain of PfCuPATPase. Since it does not have the copper binding motif, Domain 1 is unlikely to bind
the copper(I). However, it is interesting all the three domains are predicted to have a
ferredoxin-like fold. Experiments were performed to determine the structural features of
these domains.
5.1.1 Biophysical characterization of PfCuP-D1
5.1.2 Circular dichroism
A CD wavelength scan on PfCuP-D1 was performed at a 10 µM concentration in a 50
mM sodium phosphate buffer, pH 7.5. Results show that the protein is structured and
may contain both alpha helices and beta strands shown in Figure 5.0.
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Figure 5.0 CD wavelength scan for
PfCuP-MBD1. The spectra show
maxima at 197 nm, minima at 208
nm and 222 nm. The alpha helix
content was determined to be
12.8%
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MRE222 is the mean ellipticity at 222 nm and ,-. is the maximum ellipticity which is
determined by the equations:
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MRE =

0
#&34

,-. = −40000 ∗ (1 − (
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5.1.3

%&'(((
+
)*

=

?.A
#&34

*100 =

0
56∗8∗9

CDEEF?D
FI

=

?.A
# &34

)

CD.EEF?D
56∗56GH ∗6.5

Eq. 5.3

= -366723

= −4955.71621
?.A

) = -40000(1 – ( ) = - 38648.648
FI

CIOAA.F5E?5
CDPEIP.EIP

∗ 100 = 12.82%

Eq. 5.4
Eq. 5.5
Eq. 5.6
Eq. 5.7

Chemical unfolding for PfCuP-D1

PfCuP-MBD1 was found to be relatively unstable. At 2.8±0.2M GuHCl, the amount of
denatured protein is equivalent to the amount of the native protein, where FD = FN
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(Figure 5.2). A series of samples containing a fixed protein concentration (10 µM) were
mixed with guanidine hydrochloride in varying concentration. All samples were adjusted
to a fixed volume to keep the protein concentration the same. Only the GuHCl
concentration was varied between 0 M and 7.5 M. Samples were equilibrated at room
temperature for two hours and the wavelength scan spectra was collected on a JASCO J815 Spectropolarimeter. The unfolding was monitored at 222 nm, and the CD signal
plotted as a fractional denaturation ratio versus guanidine hydrochloride concentration
(Figure 5.1).
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Figure 5.1 Chemical
unfolding of PfCuP-D1
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Chemical unfolding for PfCuP-D1 is sigmoidal and the CD data was fit to a two state
model equation 4.0 using Origin graphing analysis software.

STU4 =

VW X VY 3Z[
5X 3Z[

G(∆]*( ^G_[]`*ab])
cd

G(∆]*( ^G_[]`*ab])
cd

Eq.

5.8

Sfgh is the signal intensity observed, SN is the signal intensity of protein in native state (at
0 M GuHCl), SD is the signal of fully denatured protein (at the highest GuHCl
concentration). In a two state unfolding, the protein exists either in a native state (N) or in
the denatured state (D). At zero concentration of the denaturant, the protein is in native
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state. As the concentration of the denaturant increases, the forces stabilizing the protein
are gradually disrupted and the protein begins to unfold. The fully denatured state is
obtained at the highest concentration of the denaturant. In a two state unfolding, the free
energy of unfolding can be determined according to equation 5.91
°
∆ij = ∆Gl
− m[GuHCl]
(m

Eq.

5.9

°
∆Gl
is the free energy of unfolding at zero concentration of the denaturant and ‘m’ is
(m

the slope, which is the measure of the denaturant ability to unfold a protein.2,3
Free energy is related to the equilibrium constant, Keq which is independent of the protein
concentration (Equation 5.10).
∆ij = -RTlnKeq

Eq.

5.10
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Figure 5.2 Determination of ∆G for PfCuP-D1 at 298 K.

Keq can be obtained from the fractional denaturation according to equation 5.11
t3u =

vY
5CvY

Eq.

5.11

Eq.

5.12

Where FD is given by
wj =

xy C xW
xY C xW
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YS is the CD signal at a specific GuHCl concentration, YN is the CD signal of the native
protein and YD is the CD signal of the denatured protein.
Free energy of PfCuP-D1 unfolding was determined from a plot of ∆ij against
[GuHCl], according to equation 4.1, which gives a linear relationship. ∆G°l( m is
obtained from the extrapolation of the curve to the Y axis intercept where [GuHCl] = 0.
°
(Figure 5.2). ∆Gl
for PfCuP-D1was determined to be 9.0±0.8 kJ/mol. GuHCl
(m

concentration where FD = 0.5 was determined to be 2.8±0.2 M (Figure 5.1)

5.1.4 Thermal unfolding for PfCuP-D1
10 µM of PfCuP-D1 was used to measure the thermal unfolding of the protein. The
temperature was gradually increased in 2°C/min increments to 95°C. The CD signal was
monitored at 222 nm. Figure 5.1 shows a plot of CD signal in molar ellipticity as a

Molar Ellipticity *10-6(deg.cm2.dmol-1)

function of temperature in °C.

-3

-4

-5

Figure 5.3 Thermal
denaturation of PfCuP-D1.
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The denaturation of PfCuP-D1 follows a sigmoidal, two state unfolding model. The
melting temperature for PfCuP-D1 was determined to be 68.1 ±3.6°C. Thermal free
energy of unfolding was determined by plotting lnKeq as a function of T-1(K-1) according
to the van’t Hoff equation 5.14.
lnKeq =

∆&z

+

∆V

Eq. 5.14

&

From the Van’t Hoff (equation 4.6) plot,

∆&

is the slope while

∆V
&

is the y-intercept

(Figure 5.4)
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Figure 5.4 Determination of ∆i
of the thermal denaturation of
PfCuP- D1.
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∆i was then calculated from equation 4.6 at 298 K
∆i = ∆{ - T ∆S

Eq. 5.15

∆i was determined to be 8.8±1.3 kJmol-1.

5.1.5

Biophysical characterization of PfCuP-MBD2

PfCuP-MBD2 is the second domain of PfCuP-ATPase and is the only domain that has a
copper binding motif (MXCXXC).
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5.1.6

Circular dichroism of PfCuP-MBD2

15 µM of PfCuP-MBD2 was used for the secondary structure determination of the
domain in a 30 mM sodium phosphate buffer, pH 7.5. The protein concentration was
determined using BCA assay. Figure 5.16 shows the wavelength scan for PfCuP-MBD2
at room temperature.

Molar Ellipticity *10-6(degcm2dmol-1)
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Figure 5.5 Wavelength scan
forPfCuP-MBD2.
A Minimum at 207nm, 222nm,
positive maxima at 197nm
indicates a mixture of alpha
helix and beta sheets. MBD2
has a 27% alpha helical content.
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5.1.7

Chemical unfolding of PfCuP-MBD2

PfCuP-MBD2 protein samples were buffer exchanged into a 30 mM sodium phosphate,
pH 7.5 and the concentration determined using BCA assay. A fixed protein concentration
(10 µM) was mixed with varying concentrations of GuHCl, GuHCl was prepared as a
stock solution according to the equation 5.16.
2
3
C = 57.1 7 (∆N) + 38.68 (∆N) - 91.6 (∆N)

Eq. 5.16

Where C is the concentration of GuHCl in moles/L and ∆N is the change in refractive
index between the solution and water.
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Samples were incubated at room temperature for 2 hours and unfolding was monitored at
222 nm. The CD signal, in molar ellipticity, was plotted as a function of guanidine
hydrochloride concentration (Figure 5.17 a). The protein is structurally unstable as it
begins to unfold at minimal concentration of GuHCl, and is fully unfolded at 3M GuHCl
(Figure 5.6). At 1.35 M GuHCl, FD = FN, where 50% of the protein is denatured (Figure
5.7).
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Figure 5.6 Chemical unfolding for
PfCuP-MBD2. The protein begins to
unfold when lower concentration of
denaturant is added and fully unfold at
3M GuHCl.
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Figure 5.7 Fractional denaturation of
PfCuP-MBD2. At 1.35 M GnHCl,
FD = FN.

FD

0.8

0.6

0.4

0.2

0.0
0

1

2

3

4

5

6

[GuHCl]

The denaturation of PfCuP-MBD2 reveals a two state unfolding. The protein starts to
unfold with less than 0.5 M GuHCl and at ~ 1.35 M GuHCl the amount of protein in the
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native state is equal to the amount of protein in denatured state. PfCuP-MBD2 may thus
be an unstable protein.

5.1.8

Gibbs free energy of chemical denaturation of PfCuP-MBD2 (Δijᵒ for MBD2
at 298K)

The Gibbs free energy for denaturation of PfCuP-MBD2 was determined according to
°
equation 5.10. ∆Gl
for PfCuP-MBD2 was determined to be 6.07± 1.10 kJmol-1 (Figure
(m
5.18).
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Figure 5.8 ∆Gl
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°
∆Gl
was determined by extrapolating the linear curve to Y-intercept where [GuHCl] =
(m

0. The low energy of denaturation suggests the protein is unstable.

5.1.9

Heteronuclear Single Quantum Coherence (1H, 15N HSQC) for PfCuP-MBD2

Each amino acid residue in a protein, except proline, has an amide proton that is attached
to a nitrogen in a peptide bond. 1H,15N HSQC experiments reveal the chemical shifts of
the nitrogen and the amide proton since each N-H bond produces a peak in the spectrum.
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The side chain carboximide N-H bonds in asparagine and glutamine residues are also
observed in the spectrum, and usually appear as peak doublets in the top right corner of
the spectrum (Figure 5.19). If the protein domain is structured the peaks will be well
dispersed and are generally easily distinguished from each other. Clusters of overlapped
peaks in the middle of the spectrum generally correspond to unstructured residues in the
protein. Protein size may also affect the quality of the spectrum, and proteins proteins
may not give a good HSQC spectrum. An increase in molecular size causes the molecule
to tumble slower, leads to a slower tumbling rate of the molecule, and leads to a rapid
relaxation of the excited nuclei and results in the broadening of the associated signals.
Proteins smaller than 20 kDa are routinely studied by solution NMR. The collection of a
1

H, 15N HSQC NMR spectrum requires the protein to be labeled with 15N.

Proteins constructs were isotopically labelled by expressing them in a media that contains
(15NH4)2SO4 as the sole nitrogen source. 500 µL of protein was prepared for NMR
experiments. Purified PfCuP-MBD2 was buffer exchanged into NMR buffer (30 mM
sodium phosphate, 150 mM NaCl, 1 mM DTT, pH 7.5) and concentrated to 0.6 mM.
Spectra was collected on an 800 MHZ Bruker NMR equipped with cryoprobe at the
University of Notre Dame by Professor Blair Szymczyna. The data was processed using
NMRPipe software. The PfCuP-MBD2 construct yields a well dispersed

15

N HSQC

spectrum, which suggests that Domain 2 and corroborates the circular dichroism result
(Figure 5.9).
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Figure 5.9 15N HSQC spectra for the PfCuP-MBD2. The spectrum shows
well dispersed peaks, which is a characteristic of structured proteins.

5.2 Copper metal binding affinity of PfCuP-MBD2
The metal binding affinity of PfCuP-MBD2 and PfCuP-MBD2-3 was determined
according to equation 5.17 and 5.18. 4, 5
P + [CuIL2]3- ⇌ CuI-P + 2L2-

Eq. 5.17

[}]~~
[ÄÅ]~~

= 1-

[ÄÅÉ Ñ( ]
[ÄÅ]~~

+tj Ü? (

[Ñ]áàá
[ÄÅÉ Ñ( ]

-2)2 [CuIL2]( 1-

[ÄÅÉ Ñ( ]
[ÄÅ]~~

)

Eq. 5.18

Where Ü is the formation constant for [Cuã (BCS)? ]DC = 105O.P M C?
KD is the dissociation constant for the copper-protein complex (CuI-P), P is protein, L is
the BCS ligand and CuIL2 is [Cuã (BCS)? ]DC
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Cuã and Bathocuproinedisulfonic acid (Na? BCS) forms a stable 1:2 complex
[Cuã (BCS)? ]DC with the overall formation constant β = 105O.P M C? , as determined by Xiao
et al.6 The affinity of copper binding to PfCuP-MBD2 was determined by measuring the
decrease in absorbance at 483 nm of [Cuã (BCS)? ]DC (Figure 5.10) and fitting the curve
according to equation 5.18 with Origin® (Figure 5.11 and 5.12).
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Figure 5.10 A representative spectrum
for Absorption spectra of the titration
of PfCuP-MBD2 and PfCuP-MBD2-3
against 400 îM BCS. The decrease in
absorbance was followed at 483 nm.
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Figure 5.12 determination of the
dissociation constant k D by fitting the
curve to equation 4.9.
kD was found to be 1.35 x10-18 M.
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5.3 Biophysical characterization of PfCuP-D3
PfCuP-D3 is the third predicted domain in the N-terminal portion of the PfCuP-ATPase.
The domain does not contain the copper metal binding motif (MXCXXC). It is closest to
the first predicted transmembrane domain and its separated by ten residues from PfCuPMBD2. This section describes the circular dichroism measurements and triple resonance
experiments for PfCuP-D3.

5.3.1

Circular dichroism of PfCuP-D3

Purified PfCuP-MBD3 was buffer exchanged into 50 mM sodium phosphate buffer, 150
mM NaCl, pH 7.5. 10 µM of the protein in a 1mm quartz cuvette was used for all CD
measurements. Wavelength scan spectra was collected between 195 – 300 nm at 25℃
and at a scanning rate of 100 nm/min, with three scans in each run. The alpha helical
content of PfCuP-D3 was calculated as described in Section 5.1.2 and revealed to be 16%

Molar Ellipticity *10-6(deg.cm2.dmol-1)

Figure 5.13 shows the CD spectra for PfCuP-D3.

1.0

0.5

Figure 5.13 CD wavelength scan
for PfCuP-MBD3. Percentage
alpha content was determined to
be 16%. The spectra the protein
is composed of both alpha
helices, and beta strands.
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5.3.2

Chemical unfolding of PfCuP-D3 with GuHCl

10 µM of PfCuP-MBD3 was incubated for two hours at room temperature in increasing
concentrations of GuHCl. CD signal was recorded at a 222 nm. The unfolding profile of
PfCuP-D3 is sigmoidal. The protein begins to unfold at 3 M GuHCl and is completely
denatured at 6 M GuHCl (Figure 5.14). The fractional denaturation curve shows that only
50% of the protein is denatured at 4.6 M GuHCl. (FD = FN, Figure 5.15). The Gibbs free
energy for the unfolding of PfCuP-D3 was determined to be 15.9 ± 0.8 kJmol-1 at 298 K
(Figure 5.16).
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Figure 5.14 Chemical unfolding
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5.3.3
1

PfCuP-D3 1H- 15N HSQC

H-15N HSQC is the most common experiment in protein NMR spectroscopy since it

shows all the H-N correlations, which mainly are associated with the backbone amide
groups. The spectrum is often referred to as a fingerprint of protein domains, and can
indicate that other experiments, such as triple resonance spectra, are worth pursuing. It is
also useful in assessing protein stability, foldedness, aggregation and the identifying
unstructured regions in proteins.7
The 15N labelled protein was buffer exchanged into 30 mM sodium phosphate, 150 mM
sodium chloride, and 1mM DTT. The protein was concentrated to 0.7 mM, and loaded
into a thin walled 1000 MHZ NMR tubed. The NMR data was collected using a Bruker
AVANCE II 800 MHz NMR at Notre Dame by Dr. Blair Szymczyna. The data was
processed using NMRPipe software. The 1H,

15

N HSQC spectrum (Figure 5.17) reveals

well dispersed peaks that are characteristic of a folded protein. This result implies the
protein construct is a structured domain and may be feasible for triple resonance
experiments.

Figure 5.17 1H, 15N HSQC for
PfCuP-D3.
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5.3.4

Heteronuclear NOE relaxation of PfCuP-D3

Nuclear Overhauser effect (NOE) originates from the dipole–dipole relaxation
interactions between two spin-1/2 nuclei. This implies that the NOE is dependent on
motions and the distances between the nuclei. NOEs can thus be used for the assessment
of intramolecular motions, measurements of distances and structure calculation.
Specifically, heteronuclear relaxation can thus be used to provide a detailed information
about the internal dynamics of the protein.8 The 1H-15N NOEs of PfCuP-MBD3 (Figure
5.18) reveals that about 20% of the protein is dynamic and Figure 5.19 shows the
dynamics of each residue in PfCuP-MBD3. Heteronuclear NOE values were calculated as
the ratio of peak heights in spectra recorded with and without the application of a
saturation pulse to the nitrogen atoms.
25

Number of Residues
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Figure 5.18 1H-15N Heteronuclear
NOE relaxation reveals that about 20
% of the PfCuP-D3 residues to be
dynamic.
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Figure 5.19 1H-15N Heteronuclear
NOE relaxation showing some
detailed dynamics of PfCuP-MBD3.
Negative 1H-15N NOE values,
reveals regions that are extensively
dynamic on the nanosecond time
scale, which is typical of randomcoil regions.
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5.3.5

Triple resonance experiments and resonance assignments

Backbone resonance assignments were obtained by primarily using the CBCANNH and
CBCA(CO)NNH spectra, but were supported by information derived from the HNCA,
HN(CO)CA, HNCO, and HN(CA)CO spectra. Resonances were assigned to the
backbone atoms in 74 of the 89 amino acid residues in the PfCuP-D3 construct (Figure
5.20).

Figure 5.20 Resonance assignments for PfCuP-D3.

148

The general approach used to obtain resonance assignments was described
in section 4.7.2. Table 5.1 list the chemical shifts of the amide atoms of
each amino acid that was assigned using the triple resonance experiments
collected on PfCuP-D3. Resonances that could not be assigned with 100%
certainty, due to lack of clear connectivity, were left blank. The protein
started to degrade during the data collection, especially at the C-terminus,
and resulted in the inability to assign several amino acid residues.
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Table 5.1 1H-15N chemical shifts for PfCuP-D3
PfCuP-D3
Residue #

PfCuP-ATPase
Residue #

N (ppm)

MET 1
ASP 2
ASP 3
LYS 4
ASN 5
ARG 6
CYS 7
ASN 8
LEU 9
SER 10
GLU 11
ILE 12
THR 13
LEU 14
TYR 15
ILE 16
TYR 17
ARG 18
ASP 19
ASP 20
ILE 21
LYS 22

MET 476
ASP 477
ASP 478
LYS 479
ASN 480
ARG 481
CYS 482
ASN 483
LEU 484
SER 485
GLU 486
ILE 487
THR 488
LEU 489
TYR 490
ILE 491
TYR 492
ARG 493
ASP 494
ASP 495
ILE 496
LYS 497

-

HN
(PPM)
-

LYS 23
SER 24
TYR 25
LYS 26
LEU 27
LEU 28
LYS 29
ASP 30
ILE 31
LYS 32
GLY 33
ILE 34
SER 35
ASN 36
VAL 37
GLU 38
TYR 39
ASP 40

LYS 498
SER 499
TYR 500
LYS 501
LEU 502
LEU 503
LYS 504
ASP 505
ILE 506
LYS 507
GLY 508
ILE 509
SER 510
ASN 511
VAL 512
GLU 513
TYR 514
ASP 515

121.373
118.663
121.184
119.012
120.717
120.495
118.036
123.489
118.858
124.570
123.499
127.232
123.215
121.274
122.275
118.847
125.064
121.479
117.828

8.466
8.398
8.193
8.346
8.505
7.836
8.522
8.290
7.255
9.364
8.947
7.614
8.626
8.254
8.376
8.587
7.579
8.936
8.870

LEU 41
LYS 42

LEU 516
LYS 517

118.847
123.554
115.685
117.325
117.286
112.551
117.202
123.068
130.681
111.798
122.528
122.311
117.275
116.652
128.690
116.284
119.829
124.803

7.356
8.829
7.615
6.871
8.140
7.526
6.966
7.328
8.531
8.718
7.754
9.431
8.902
8.257
9.965
8.399
8.163
9.062

118.782

8.184
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PfCuP-D3
Residue #

PfCuP-ATPase
Residue #

N (ppm)

TYR 45
ILE 46
TYR 47
PHE 48
LEU 49
TYR 50
ASP 51
PRO 52
GLU 53
LEU 54
VAL 55
GLY 56
ILE 57
ARG 58
TYR 59
ILE 60
LEU 61
GLU 62
ILE 63
LEU 64
LYS 65
LYS 66

TYR 520
ILE 521
TYR 522
PHE 523
LEU 524
TYR 525
ASP 526
PRO 527
GLU 528
LEU 529
VAL 530
GLY 531
ILE 532
ARG 533
TYR 534
ILE 535
LEU 536
GLU 537
ILE 538
LEU 539
LYS 540
LYS 541

111.811

HN
(ppm)
7.549

LYS 67
LYS 68
ASN 69
VAL 70
ASP 71

LYS 542
LYS 543
ASN 544
VAL 545
ASP 546

117.918
130.192
118.791
115.906
116.857
120.510
116.914
118.325
120.122
108.684
121.256
122.351
122.406
122.992
117.182
120.307
119.589
122.056
119.650
119.334
-

9.203
9.505
7.814
8.206
9.199
8.120
8.410
7.949
8.424
7.425
8.353
8.034
7.935
7.935
8.186
8.025
7.560
7.808
7.463
9.059
-

TYR 73
TYR 74
ASP 75
GLU 76
ASP 77
LYS 78
GLU 79
LYS 80
TYR 81
PHE 82
ARG 83
SER 84

TYR 548
TYR 549
ASP 550
GLU 551
ASP 552
LYS 553
GLU 554
LYS 555
TYR 556
PHE 557
ARG 558
SER 559

122.507
118.002
120.878
127.390
119.356
115.264
123.495

7.903
7.693
7.693
8.513
8.484
7.935
8.920

SER 85
GLN 86

SER 560
GLN 561

Table 5.1 1H-15N chemical shifts for PfCuP-D3—Continued
PfCuP-D3
Residue #

PfCuP-ATPase
Residue #

N (ppm)

HN
(PPM)

PfCuP-D3
Residue #

PfCuP-ATPase
Residue #

LYS 43

LYS 518

117.975

8.304

ASN 87

ASN 562

GLU 44

GLU 519

114.947

7.521

ASN 88
GLU 89

ASN 563
GLU 564

5.3.6

N (ppm)

HN
(ppm)

Secondary structure prediction based on chemical shifts

The secondary structure of PfCuP-D3 was predicted using PINE-SPARKY using the
assigned chemical shifts shown on Table 5.35. The prediction indicates that the fist 75
residues of PfCuP-D3- has a ferredoxin fold. This corresponds to the amino acids
residues 480 -550 of the native protein (Figure 5.36).

Figure 5.21 Secondary structure prediction based on the chemical shift assignments. The prediction
reveals that PfCuP-D3 has ferredoxin fold, Ü#ÜÜ#Ü.
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5.4 Biophysical characterization of PfCuP-MBD2-3
5.4.1

Circular dichroism measurements of PfCuP-MBD2-3

10µM of PfCuP-MB2-3 was used for the CD wavelength scan. Results shows that the
PfCuP-MB2-3 has maxima at 198nm and three minima at 212 nm, 218 nm and 222 nm
(Figure 5.22).
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Figure 5.22 CD spectra for PfCuPMBD2-3. The alpha helical
content was determined to be 12%
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5.4.2

Chemical denaturation of PfCuP-MBD2-3 using GuHCl

It was determined that PfCuP-MBD2-3 unfolds in a three state model (Figure 5.23). This
is because Domains 2 and 3 are independently unfolded.

Molar Ellipticity *10 -6 (deg.cm2.dmol-1)

0.5
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
-3.5
-4.0
-4.5
-5.0
-1

0

1

2

3

4

5

6

7

8

[ GuHCl ]

Figure 5.23 PfCuP-MBD2-3 unfolds in three transition states.
The protein forms a stable intermediate (I) as it transitions from its native (N) to denatured state (D). A plot
of CD signal against the denaturant concentration give a double sigmoidal curve showing the transition of
the protein from N→ I and I→ D. These transitions will have different ∆iand m values. These were
obtained from the curve fitting of the plot to equation 5.19
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Eq. 5.19
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The free energies of unfolding for PfCuP-MBD2-3 are summarized in Table 5.2
Table 5.2: Free energies and m values of denaturation of PfCuP-MBD2-3
Transition state
N→ I
I→ D

m(kJmol-1)
6.3±0.6
7.8±0.6

∆"(kJmol-1)
11.4±1.2
21.4±3.1

[GuHCl]
1.3±0.3
4.9±0.4

The transition at 1.3 M GuHCl corresponds to the unfolding of domain two (Section
5.1.7) while the transition at 4.9 M GuHCl corresponds to the unfolding of domain three
(Section 5.3.2).

5.4.3

Thermal unfolding of PfCuP-MBD2-3

Thermal unfolding for PfCuP-MBD2-3 was performed on a 10 µM sample. Temperature
was increased gradually from 25ºC to 95ºC at a rate of 1ºC/min and the CD signal was
recorded at 222 nm. Figure 5.24 shows a sigmoidal curve for the thermal denaturation of

Molar Ellipticity *10 -6 (deg.cm2.dmol-1)

PfCuP-MBD2-3. The temperature midpoint of the protein was found to be 47.9 ±0.7ºC.
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Figure 5.24
Thermal unfolding for PfCuP-MBD23.
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The thermodynamic properties, ∆H and ∆S were obtained from the Van’t Hoff relation,
equation 5.14.

Keq was calculated from equation 5.12 and 5.13. A plot of ln(Keq)

against T-1 gives a linear curve where enthalpy ∆H can be obtained from the slope, and
the change in entropy ∆S will be obtained from the y-intercept (Figure 5.25).
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Figure 5.25 Determination of free
energy of thermal unfolding for
PfCuP-MBD2-3. Using equation 5.15,
free energy of thermal denaturation of
PfCuP-MBD2-3 at 298 K was found to
be 17.9± 0.4 kJ/mol.
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5.4.4

Copper metal binding affinity of PfCuP-MBD2-3

PfCuP-MBD2-3 has one metal binding motif (MXCXXC) at domain 2. Purified protein
was reduced with excess DTT and titrated against the CuI[BCS2]3- complex. The binding
of copper to the protein was followed by measuring the decrease of absorbance at 483
nm. The experiment was done under anaerobic conditions, as described in section 4.8.
Two sets of titrations were performed at 400 µM CuI[BCS2]3- and 500 µM CuI[BCS2]3Figure 5.26 shows a plot of [CuI(BCS)2]3- versus PfCuP-MBD2-3: Cu. The data was then
fit to a curve according to equation 5.18 (Figure 5.27 and 5.28).
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Figure 5.26 Titration of
PfCuP-MBD2-3 against 500
2M BCS (red spheres) and 400
2M BCS (black spheres).
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Figure 5.27 Curve fitting of the
titration of PfCuP-MBD2-3 against
500 2M [Cu1 (BCS)2]3. KD was
determined to be 2.4 * 10 -18 M.
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Figure 5.28 Curve fitting of the titration
of PfCuP-MBD2-3 against 400 2M [Cu1
(BCS)2]3-. KD was determined to be 1.3 *
10 -18 M.
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5.5 Summary
This chapter discussed the biophysical characterization of the N-terminal domains of
PfCuP-ATPase using circular dichroism, metal affinity assays and solution NMR
spectroscopy. The alpha helical content of each domain as calculated using circular
dichroism, ranges between 12-27% which is within the range typical of globular proteins,
which have an average of 30% alpha helical content.9 The stability of the protein
constructs was assessed using chemical denaturation with guanidine hydrochloride and
thermal denaturation, by gradually heating the protein from 25℃ – 95℃. Domain 1 of
PfCuP-ATPase retained 50% of its structure at 2.8 M GuHCl, Domain 2 is the least stable
since it begins to unfold with only 0.35 M GuHCl, and retains 50% of its structure at 1.35
M GuHCl. Domain 3 is the most stable of the three domains since it retains 50 % of its
structure at 4.6 M GuHCl. Domains 1 through 3 unfold in a two phase manner as
concentration of the concentration of denaturant is gradually increased. When domains 2
and 3 are joined together as one protein construct, the protein displays a double sigmoidal
unfolding curve. The first midpoint is consistent to the unfolding of domain 2 where 50%
of the protein retains its structure at 3 M GuHCl, and the second midpoint at 4.9 M
GuHCl, that corresponds with the unfolding of domain 3. Only Domain 1 and Domain 23 constructs were thermally denatured. Domains 2 and 3 constructs precipitated as they
were heated. This may be due to structural rearrangement of the domains that might have
occurred during heating that may have resulted in the aggregation of the proteins.
Solution NMR and the circular dichroism data corroborates the prediction that PfCuPATPase has three independent N-terminal domains.
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Metal binding affinity assays shows that constructs for domain 2 and a construct of
Domain 2 and 3 joined together are able to bind copper with a high affinity. Domain 2
has KD of 1.35 * 10

-18

found to be 1.85 * 10

M while the affinity for copper for Domain 2-3 construct was

-18

M. The copper affinity for PfCuP-MBD2 and PfCuP-MBD2-3

compares well with copper affinity for Atox1 and Wilson disease domain 5-6.4
Triple resonance experiments were acquired on Domain 3 and the resonances assigned,
as detailed in section 4.3.5. Domain 3 was cloned and had a total of eighty-nine amino
acids residues, spanning residue 476 to 564 in the full length PfCuP-ATPase. As seen
from Table 5.5, resonances that were assigned are between residue numbers 479 and 549.
It was determined that the protein began to degrade and did not remain stable at the end
of the data collection week. This confirmed by a lack of connectivity during the
assignment of resonances corresponding to C-terminal residues. Future experiments
should be repeated with protease inhibitors added. However, since the majority of the
peaks were assigned, it is possible to obtain a CS Rosetta predicted model of the
structure. Using PINE SPARKY software, secondary structure prediction of PfCuP-D3
based on the chemical shift assignments reveals that PfCuP-D3 has ferredoxin fold,
454454.
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CHAPTER 6
COPPER BINDING AFFINITIES OF DICTYOSTELIUM DISCOIDEUM COPPER
CHAPERONE ATOX1 AND METAL BINDING DOMAIN ONE OF COPPER PTYPE ATPASE 1

6.1 Introduction
Dictyostelium discoideum is a slime mold, free-living amoeba that inhabits the upper
layer of forest soil that is rich in organic material. It feeds mainly on bacteria by
phagocytosis and thus could be a natural source of pathogenic bacteria. During starvation,
amoeba solitary cells aggregate through chemotaxis to form multicellular organisms.1,2
The multicellular organisms, called slugs, migrates towards warmth and light in search of
a suitable environment for fruiting body formation.1 These cells differentiate into prestalk and pre-spores that migrate and grow into a fruiting body made of slender stalks
and fully differentiated spores on top. Because of their easy handling and amenability to
genetic manipulation, Dictyostelium discoideum has been a valuable model organism for
studies such as motility, chemotaxis, morphogenesis, and host resistance to infection and
the hosts’ interaction with many clinically relevant bacterial pathogens.3, 4, 5

6.2 Metal ion homeostasis in Dictyostelium discoideum
Various divalent transitional metal ions have been involved in host pathogen interactions,
such as, manganese, copper and zinc.6 Iron and manganese are depleted from the mature
phagosome, while copper and zinc are thought to be pumped into the phagosome to
intoxicate the bacteria. This is supported by the finding that increased concentrations of
copper and zinc are found in mycobacterial infections.7 The development of
Dictyostelium discoideum is sensitive to the presence of heavy metals in the soil. Higher
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concentrations of mercury (50 mg/kg of soil) inhibit protozoan growth, more so than
high concentrations of manganese, iron and copper.8,9
6.3 Copper ion metabolism in Dictyostelium discoideum
Dictyostelium discoideum is a social amoeba has three genes for copper ATPases: ATP1
(gene ID: 8618898) which encodes a 1280 amino acid residue protein, ATP7A,
(GenBank: EAL65411.1) which encodes a protein of 985 amino acid residues and ATP3,
GenID: 8617046 which encodes a protein with 1386 amino acid residues. The
Dictyostelium genome encodes also encodes a putative copper transporter, p80, that is
localized in the plasma membrane and in the phagosome. The p80 copper transporter is a
Ctr1 homologue. Burlando et al. discovered that Dictyostelium discoideum has unusual
copper resistance. The resistance was associated with the presence of a copper ATPase
homologue of MNK protein, which uses copper ions to kill bacteria.10 Other possible
copper proteins (DDB_G0288281gene ) present in the protozoan are metallothioneins,
which are cysteine-rich proteins that binds heavy metals through their thiol groups. The
presence of metallothioneins is yet to be determined. Burlando et al. used a cytochemical
technique and Western blotting to demonstrate the occurrence of Cu-ATPase activity.
The 105 kDa apparent molecular weight of the ATPase determined by Western blot,
agrees well with the Cu-ATPases with a molecular weight of 100 kDa to 150 kDa .10
6.4 Involvement of copper and zinc metal ions in the phagosomal killing of bacteria
The copper ion is used by many metalloenzymes, but an excess is detrimental to cells.
Prokaryotes must have mechanisms that maintain copper homeostasis, and allow the
accumulation of ions in the intracellular organelles and their eventual utilization in a
particular biological activity. Macrophages utilize Zn(II) and Cu(I) to destroy Fe-S
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clusters that are essential for the survival of bacteria.

11, 12, 13,14

The entry of copper ions

in the amoeba is facilitated by a copper transporter protein p80, a membrane bound
protein which is homologous to human and yeast copper transporter 1.11 By analogy to
yeast and humans, inside the protozoan cell, a copper chaperone Atox1 receives the Cu(I)
ion and transports it to ATP7A, a TM protein that is localized in the trans Golgi network.
ATP7A eventually transfers the copper ions to the phagosome where it is involved in
killing and digesting of bacteria. As a defense mechanism, the bacteria also express
copper ATPase (CopA) for the efflux of the copper ions, and a Zinc ATPase (ZntA) for
the efflux of the zinc ions (Figure 6.0).

Figure 6.0 Metal ions and their involvement if phagosomal bacterial killing.
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Dictyostelium discoideum expresses three copper ATPases: ATP7A, ATP1, and ATP3.
ATP7A is localized in the membrane of TGN while ATP1 and ATP3 may also be
localized in the TGN, however their exact localization has not been elucidated. ATP7A,
ATP1 and ATP3 bind copper in the form of Cu(I). The removal of iron and manganese
ion from the phagosome is facilitated by the natural resistance-associated macrophage
protein 1 (NRMP1). E.coli expresses ZntA and CopA used for the efflux of zinc and
copper ions respectively. CusCBA is required for the removal of the periplasmic copper.
There is little information available on the ATP7A, ATP1 and ATP3 copper ATPases of
the Dictyostelium discoideum.

6.5 N-terminal domain of Dictyostelium discoideum ATP1
ATP1 has 1280 amino acid residues. The N-terminal portion of the protein has two
copper binding motifs (MKCXXXC and MTCXXC).

The protein sequence was

analyzed using Jpred 4 (a protein secondary structure prediction server) to predict the
structured regions of the protein. The sequences of the structured portions of the protein
were then modelled using Phyre2 (an online server for predicting the 3-dimensional
structure of a protein) and SWISS-MODEL (an online server for protein structure
homology-modelling). Of all the models of homologues from Phyre2, a model of a
template with the highest degree of confidence (100%) and percent identity were selected
and processed further using PyMOLTM. The resulting prediction of the metal binding
domains of ATP1 are shown in Figures 6.1 and 6.2. In all the models Wilson disease
protein metal binding domains (PDB: 2EW9 and 2ROP) were used as the template.
Modeling of this ATP1 suggested the protein has two metal binding domains. These two
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domains are predicted to have 69 residues (residues 201-270 for Domain 1) and (residues
356-425) for Domain 2 respectively. The domains are predicted to have a ferredoxin fold
similar to the Menkes and Wilson disease proteins metal binding domains. Domains 1
and 2 were modeled using a template of solution structures of the Wilson disease protein
domain 5 and 6 (PDB: 2EW9), and domain 3 and 4 (PDB: 2ROP).

Figure 6.1 N-terminal metal binding domain 1 of ATP1 with MKCXXXC copper binding motif. The
cysteine residues, shown in sticks are located in the loop connecting β1 and α1

Figure 6.2 N-terminal domain 2 of ATP1 with MTCXXC copper binding motif. The two cysteine residues
are shown in sticks are located at the end of the loop of β1 and at the beginning of α1 helix.

6.6 Dictyostelium discoideum copper chaperone Atox1 (DdAtox1)
Dictyostelium discoideum has a copper chaperone (DdAtox1) for delivery of Cu(I) to
ATP7A. The delivery of Cu(I) to ATP1 and ATP3 has been documented in literature.
DdAtox1 has 67 amino acid residues. It is predicted to have a ferredoxin fold similar to
human copper chaperone (HAH1).
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6.7 Expression and purification of DdAtox1 and the metal binding domains 1 and 2
of ATP1
Plasmids containing the genes encoding DdAtox1 and the N-terminal domains were
purchased from GenScript Inc. The genes were synthesized in order to utilize codon
optimization and overcome anticipated protein expression challenges in E. coli. The
synthesized genes were cloned into the pET-28(b) expression plasmid, which has a
Histidine tag at the C-terminus. The TEV protease site was introduced at the end of the
protein such that the affinity tag will be cleaved off with the protease during the
purification steps. BL21(DE3) competent cells were transformed with 60 ng of plasmid
DNA. The colonies were grown overnight at 37ºC for 16 hours. One colony was then
used to inoculate a starter culture of 5 mL LB media with kanamycin. The starter culture
was grown for 6 hours then scaled up to 500 mL LB growth media in a 2 L flask. The
protein expression was induced by addition of IPTG when O.D at 600 nm was 0.6. The
protein was expressed for 5 hours at room temperature. The cells were harvested by
centrifugation and the cells were resuspended in a lysis buffer A containing 30 mM
sodium phosphate buffer pH 7.5, 150 mM sodium chloride, 0.5 mM EDTA. The cells
were raptured by sonication and then centrifuged. The supernatant containing the soluble
proteins was loaded into a HisTrap HP column (GE Healthcare Life Sciences) preequilibrated with binding buffer: 30 mM sodium phosphate buffer pH 7.5, 150 mM
sodium chloride, and 20 mM imidazole. The column was washed with five column
volumes of binding buffer. The protein was then eluted by gradient using elution buffer:
30 mM sodium phosphate buffer pH 7.5, 150 mM sodium chloride, and 300 mM
imidazole. Fractions containing DdAtox1 were combined together, concentrated by
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Amicon filtration device fitted with 3.0 kDa NMWL (nominal molecular weight limit)
membrane. The protein was then buffer exchanged into 50 mM Tris-HCl, pH 8.0.
Protein concentration was determined by BCA assay and the TEV protease added at a
mass ratio of 80:1, (protein/protease). The protein was digested overnight at room
temperature and the protein was passed through HisTrap column to remove the His6 tag.
Protein without His6 tag was collected as a flow through, then buffer exchanged into 30
mM sodium phosphate, 150 mM sodium chloride, 1 mM DTT, pH 7.5. Protein yield was
11.6 mg for a 1L growth media.
For 1H-15N HSQC NMR sample preparation, the protein was expressed and purified in
the same manner as described in section 4.4.1, except the protein was expressed in E. coli
in M9 minimal media, which contained isotopically labeled (15NH4)2SO4 as the only
nitrogen and carbon source respectively. The purity of the proteins was assessed using
SDS-PAGE (Figure 6.3).

a

b

c

Figure 6.3 (a) Purification of DdAtox1. L; protein marker, 1; cell lysate, 2; His trap fraction, 3&4; pure
DdAtox1 without the affinity tag. (b) Purification of DdATP1-MBD1. L; protein marker, 1; cell lysate, 2;
His trap fraction, 3 &4; pure protein after removal of affinity tag. (c) Purification of DdATP1-MBD2. L;
protein marker, 1; His trap fraction, 2; pure protein without the affinity tag.
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6. 8 Heteronuclear Single Quantum Coherence (1H-15N HSQC) for DdATP1-MBD1,
DdATP1-MBD2 and DdAtox1
Purified 15N labelled proteins were buffer exchanged into 30 mM sodium phosphate, 150
NaCl mM, and 1 mM DTT, pH 7.5 using PD10 desalting columns. Protein were
concentrated to 0.6 mM for NMR spectroscopy studies. All buffers used were made fresh
and degassed before use. Dr. Blair Szymczyna collected the NMR spectra on a Bruker
AVANCE II 800 MHz NMR at the University of Notre Dame by Dr. Blair Szymczyna.
The data was processed using NMRPipe. The 1H,15N HSQC spectra for DdAtox1,
DdATP1-MBD1and DdATP1-MBD2 reveals that the resonances are well dispersed,
which a characteristic of a structured protein (Figures 6.4, a, b and c).
a

b

c

Figure 6.4 1H-15N HSQC spectra
for (a) DdAtox1, (b) DdATP1MBD1, and (c) DdATP1-MBD2
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6.9 Copper metal binding affinity of DdATP1-MBD1 and DdAtox1
Purified proteins were titrated against two different concentrations of competing ligand
bathocuproinedisulfonate (BCS), which forms a 2:1 complex with CuI. All copper
binding experiments were performed under anaerobic conditions in a glovebox as
described in Section 4.7.4 Figures 6.5 - 6.10 shows the corresponding titration curves of
the [CuI(BCS)2]3- against protein copper ration and the curve fitting to equation 5.18 in
order to determine the affinity constants...
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Figure 6.5 Titration of
DdAtox1 against
[CuI(BCS)2]3- (500µM,
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Figure 6.6 Curve fitting of the
titration of DdAtox1 to 400
µM [CuI(BCS)2]3-. KD was
found to be 1.4 * 10-18 M.
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Figure 6.7 Curve fitting of the
titration of DdAtox1 to 500
µM [CuI(BCS)2]3-. KD was
found to be 2.01 * 10-18 M.
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Figure 6.9 Curve fitting of
the titration of DdATP11 to
300 µM [CuI(BCS)2]3-. K D
was found to be 2.1 * 10-18
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Figure 6.10 Curve fitting of
the titration of DdATP1 to 400
µM [CuI(BCS)2]3-. KD was
found to be 2.4 * 10-18 M.
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6.10 Summary and future work
In this work, it has been shown that the N-terminal domain of copper ATPase 1 of
Dictyostelium discoideum has two metal binding domains. This is evidenced by the
Heteronuclear Single Quantum Coherence (1H-15N HSQC) spectra (Figure 6.8) that
suggests the domains have a tertiary structure. The binding affinity values calculated
from the curve fitting of the titrations against 400 and 500 µM [CuI(BCS)2]3- were
averaged and adopted as the affinity constants of the protein. The affinity constant for
metal binding domain one of DdATP1 was found to be 2.3 * 10-18 M while that of the
copper chaperone DdAtox1 was found to be 1.7 * 10-18 M. The metal affinity for
DdAtox1and DdATP1 are similar to those reported in literature for Wilson disease
domains 5-6 and Atox1.15 These result taken together shows that Domain 1 of DdATP1
has a higher affinity for copper compared to the metal chaperone DdAtox1. This is
particularly important for the chaperone to be able to donate the copper ion to the efflux
protein. The binding affinity of the second domain has not yet been determined. Future
experiments could be designed compare the affinity for metal binding domain two which
has the conserved MXCXXC motif for metal binding in contrast to Domain 1 that has the
MXCXXXC motif, and whether Domain 1 can transfer the copper ion to Domain 2.
There is no structure of a metal binding domain of P-type Copper ATPase with a
MXCXXXC motif. It would be of interest to determine the structure of this domain and
and determine if it adopts a ferredoxin fold, which is a characteristic of the N-terminal
domains of copper transport proteins.
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CHAPTER 7
DISSERTATION SUMMARY AND FUTURE WORK

7.1 Dissertation summary
Copper transport proteins are required for the maintenance of the copper levels in living
systems. Understanding structural organization of these copper ATPases sheds more light on their
mode of action. In this work, four copper transport proteins have been studied. Wilson disease
protein, ATP7B, which is involved in the copper metabolism in humans was cloned and expressed
in E. coli. Six expression vectors were prepared and different strains of E. coli competent cells
tested for the expression of the ATP7B gene. The full length ATP7B gene lacking the first 57
amino acid residues was amplified by PCR and the insert DNA of 4235 bp was cloned into βpET28a(+)-α plasmid, a derivative of pET28a(+) vector encoding two fusion domains, α and β,
that enhances the expression of membrane proteins on E.coli. Small scale protein expression was
achieved with C41(DE3) and C43(DE3) strains of E. coli cells at 18°C. Attempts to scale up the
expression was unsuccessful. It was observed that the large scale expression of the protein resulted
to cell death and the project was no longer feasible.
In the second project, metal binding domain four of Wilson disease protein was fused to a
copper chaperone, HAH1 to form a 20.7 kDa chimera of two domains separated by 57 residue
linker. The protein was found to be very stable and relatively resistant to chemical and thermal
denaturation. Using Guanidine chloride as a denaturant, the protein was shown to unfold into three
phase transition states: native intermediate and denatured state respectively, as the concentration
of the denaturant was increased. The mid-point for the first transition occurs at 1.37 M GuHCl
while the second mid-point transition occurs at 5.6 M GuHCl. This corresponds to the unfolding
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of HAH1 and domain four of Wilson disease protein respectively. Gibbs free energy of chemical
unfolding was revealed to be 6.1 kJ/mol in the first transition and 44.8 kJ/mol in the second
transition. The higher energy of unfolding in the second transition is due to the high stability of
domain four which unfold in the second transition. Thermal unfolding of the chimera was
monitored at 222 nm as the protein was heated gradually from 25°C to 98°C. It was revealed that
the thermal mid-point of unfolding of the chimera is 78°C.
Following stability studied of the chimera, crystallization trials were performed at room
temperature using Hampton’s crystallization screens by hanging drop diffusion method.
Crystallization was initiated using horse hair as a nucleating agent. Crystals that grew on horse
hair were harvested and used for seeding to grow secondary crystals. The crystals were exposed
exposed to an X-ray beam at the advanced photon source at Argonne national laboratory. Poor
diffraction of the crystals made it impossible to obtain diffraction data for structural analysis.
The third project involved the determination of the N-terminal domains of Plasmodium
falciparum copper ATPase (PfCuP-ATPase). Copper metabolism in Plasmodium falciparum is
regulated by a PfCuP-ATPase, a copper efflux protein that reduces copper toxicity. PfCuP-ATPase
is the largest copper transporter of the PIB P-type ATPase family made up of 2563 amino acid
residues with a molecular weight of 298.8 kDa. The number of metal-binding domains in copper
ATPases varies among organisms. In PfCuP-ATPase, the number of metal-binding domains and
how the copper ATPase functions is only partially understood. Using bioinformatics tools, circular
dichroism and solution NMR, I have identified three N-terminal domains of PfCuP-ATPase found
within the first 564 amino acids. Surprisingly, only one domain contains the copper binding motif
MXCXXC. There is a long linker of 320 amino acids between the first and the second domains,
and the second domain is directly adjacent to domain three.
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I pursued biophysical studies to better understand the structural organization of these
domains. Each domain was separately cloned using recombinant technology and expressed in E.
coli. Domain three is the most soluble and relatively resistant to chemical denaturation with
guanidine hydrochloride. In contrast, domain two is less stable. It retains only 50% of its helical
structure at 1.35 M GuHCl. Strikingly, domain one is resistant to thermal denaturation and it has
a melting midpoint of 78°C. Domains two and three, when heated, precipitate out of solution.
However, when they are expressed together as a two-domain construct (PfCuP-MBD2-3), thermal
denaturation shows a sigmoidal curve with a melting midpoint of 47.9˚C. The chemical
denaturation of PfCuP-MBD2-3 produced a double sigmoidal curve and the second sigmoid
correlates to the denaturation of domain three. Copper binding studies were performed under
anaerobic conditions with CuI(CH3CN)4+ as the copper source, and I obtained a KD of 1.35 * 1018

M. The copper ATPase of P. falciparum diverges from that of the kingdom Animalia. The

presence of a two domain construct, like that of human Wilson protein metal-binding domains five
and six, yet lacking a metal-binding motif in domain three is intriguing. This finding highlights
the structural versatility and stability of the dual ferredoxin fold.
15

N-labelled samples were prepared and 1H-15N HSQC NMR experiments were performed

for four different constructs. Subsequently, an 13C,15N sample of domain three was prepared and
triple resonance NMR experiments were performed. NMR resonance assignments and subsequent
Rosetta modelling shows domain three to have a ferredoxin fold that is similar to the metal binding
domains of human Wilson disease protein.
The fourth project involved the determination of the copper binding affinities of N-terminal
domains of Dictyostelium discoideum copper ATPase (DdATP1) and a copper chaperone for
Dictyostelium discoideum copper ATPase (DdAtox1). In this project I was able to identify two N176

terminal metal binding domains of DdATP1. Domain 1 has unusual MXCXXXC copper binding
motif that is not common in copper transport proteins. Domain 1 and 2 of DdATP1, and DdATox1
were cloned into pET24(d+) and expressed in E. coli. Proteins were purified using metal ion
affinity chromatography. The 1H-15N HSQC spectra revealed that the proteins are structured
domains. Copper titrations experiments were done under anaerobic conditions in a glovebox. The
copper binding affinity for Domain 1 of DdATP1 was found to be 2.3 * 10-18 M, while that of
DdAtox1 was 1.7 * 10-18 M. Table 7.0 summarizes the biophysical properties of each protein
construct studied.
Table 7.0
Protein
construct

Tm(℃)
Melting
temperature

PfCuP-D1

68.1±3.6

2.8± 0.2

°
∆G%
&'
(kJ/mol)
Gibbs free
energy of
chemical
unfolding
9.0± 0.8

PfCuP-D2

Protein
aggregates
Protein
aggregates
47.9±0.7

1.4±0.1

6.1±1.1

4.6

15.9±1.2

(1st) 1.3±0.3

(1st) 11.4±1.3

(2nd) 4.9±0.4

(2nd) 21.4±3.1

PfCuP-D3
PfCuP-D2-3

Cm(M)
[GuHCl] at
midpoint

°
∆G%
&'
(kJ/mol)
Gibbs free
energy of
thermal
unfolding
8.8±1.3

KD
Dissociation
constant

1.35 x 10-18M

17.0±0.4

1.85 x 10-18M

DdATP1

2.3 x 10-18M

DdAtox1

1.7 x 10-18M

WLN5-6 1

1.9 x 10-18M

Atox11

4.4 x 10-18M
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7.2 Research significance
In this work, three N-terminal domains of PfCuP-ATPase, and two N-terminal metal binding
domains of DdATP1 have been identified. These domains have not been previously mentioned in
literature and it is the first time they have been characterized. The results described in this work
adds to the information available in literature and contributes to the scientific community towards
understanding the structure and function of these enzymes. The existence of two cytosolic domains
in PfCuP-ATPase lacking the metal binding binding motif is intriguing. This opens a new area of
study to investigate the role of these domains in the overall function of the ATPase.

7.3 Future work
The knowledge gained in this work regarding the existence three N-terminal domains in PfCuPATPase could be pursued further in order to solve their solution or crystal structures and determine
their function if they bind other metals, and their function in association with the rest of the protein.
It will be interesting to determine their significance in the ATPase since this domain is absent in
other copper ATPases. Other domains within the protein have also been identified as detailed in
the sequence shown in figure 7.0.
Figure 7.0 PfCuP-ATPase sequence
MAKLSLTINNVDDDLKRKIKKAKFEGVEDLKHKNKKLTISYNPKVVDSYGVIERIKHLDINGE
ILKDDNDISSKNGNSFTFSMYKEGVEENVVKKANIFDDNENMQNTNNYIDNNSNNCNNLYGIN
NRDNYDKLDCNGNNADNNFDQIYDMNNMVNNYTYPNGEDLYEQLDNAYDDKNYKDNYKNYETN
HQKCEQNYKNYEAIHQKCEQNYKNYEANHQKCEQNYKNYESNHQNHEQNYKSYGDNYQNCNVS
EKNENINSNYNSTNNKGDLYDINYYPNQVEKVEESEGVDENRKSSKFSVLNLFNNIKKSKDKK
KMKKEIKKDYLNEDYNNLDKRILLSNDMYKNVENKNYNNSNDNYNSNNNYYYDYNEEKLKKKN
FNFRDYESYRDKQNIYICELKIYNMTCDNCGKKIINFLKDKKLILEGNSFATDNKIKLKIDIS
SDIIHCNNNVKMFVNTIMNEIKESGFNNDLLDLYKDDKNRCNLSEITLYIYRDDIKKSYKLLK
DIKGISNVEYDLKKEYIYFLYDPELVGIRYILEILKKKKNVDAYYDEDKEKYFRSSQNNETNN
TWKLIELSICIIISIIIIVLNKYQMNMGSMNGFYSYTKKLFDNSNKIDTDNIKHPSIYHNIGN
GTPVDQSTLDIYFENVTKGKTLNEYVHKQSRRDEKGTFFINSNFKFIKKNKDSPINRKWVDDD
IKKGQILNGKKNKSIEYNNTINMLNDQIDAGHYNNQEGHKDYPLDNENNVSKYIECTNSENRR
KNYLLNEKDDDDNNKEKNINNNDNNNDEKNDNFNNDYNKDDYYDDEHYDIIPIGDFRKSDISE
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KHPDNKKGDNTKNGYSRFRKHINTNLKNKNNKNESDGEEEKGNIDGIYILKQKNHKKDMIKGE
EENKDNFSKKEEKSDNENSNEEIDKNYNYLKRKEKDHNSSNDEDNINDSVLKENVKEEEIHES
SSNEQSDSYLKKIEKKDNKNISVDNNENDNFLKKKEMKDVNNENEENRESSSLLKENKKKDNK
NISVENNENDNFLKKNEMEDQNNKHVGSNVGDIVLKKNKKKDNKNTNDENNENDNFLKKKEKL
YNNSSNEQNEENENFLKKKENTDNKNTNIQDKQNAIFLKNKKKKDDKNSKEENDESDNFLKKK
VRTEDKNTNGQDKQDDIFLKNKQNDNVKSSHDQDNQNDDTFLKKKKIKDKNDNSNDEGNVSSL
MLSKKEDENKSKNKKCDTNNSKDNIGEDNLGVSKEQDGKDSQDVKGGKHGQDVKDDKDEQDVK
GGKHGQDVKDDKDEQDVKDGKHGQDVKGGKHGQDVKDDKDEQDVKDGKHGQDVKDDNDEQDVK
DDKDEQDVKDDKDEQDVKDDNDEQDVKDDKDEQDVKDDKDEQNVKDDFKEDKDIKGGKHGQDV
KNDKHGQDVKNVKHGDVVKDGENENDSYDETEEDNFLMKKKEKKDENSTKDEKENIVMRKNKN
SEISNEENNATYENENIFMNKNKSYNNSYKNEGNDDSLFSFNNLFYKLANYSIYLDMDTKIVK
GLSLRLFFIFVLSSFVYIYYGFSFVLNGYKNLKNNMINMNVLISISSSFSYFYSLLLLLFCLI
FSIDLNGIPLYFDSSALLICIMKFGCEIENFLVSFSKKKMEDLYESTAKNVYILEKKNRYYQD
EEGNFNSNIPIKSMSNISKAFSKDNNSNSIIANSQINSNDILQSVGKENIKVDTLKNNLSFST
SSFFLSNQFLYDDDEINKILSQDMDININDYNINSYPVQFIQKNDILIFYEGSTLLIDGIKINK
GISCVDESMISGEKNAIKKYKGDKVYAGSKCVEGVVIIYVKDISKGNYIEYVKQTLDEINCKKT
NLQLYADKIASIFIPFILILCIVVFFIWFILTFFDIVNIKKENYFKLNRFLSCVFFSVHFSLSI
LCVACPCAVGLASPLSIAISTYICSSIGIIIKNINIFEIFLECKHFIFDKTGTLTVGKPVVNKI
YISNNIDLFIDQLLKNKSGNHLSVSFNDNKNAKMPALVRAKSDEKKVKKMNNNMKDNVNKLYST
AYSINDQPSNGYNGYMNNFDEQGLEGNENMMKNNTLNFVENFSCCNKNVSFYSFTTEKEYFKIE
IKKTSRNRDKVKKKKKYTKNETRNNYDESSLSGDKNYQNYQNYQNDQNDQIVSNSCMGENKSIL
NSIVSFITDKNKKNKYNKILDNSLKEHFINNSDNYFSSNDDSYYSETTSNENEHNKYDNIPVSN
NIMDQHDHLQNMSSPLEEENSYMEKSSDWLYLFLSLSLNIEKYSNHLFATSINTYINNNFSINE
VFDVNNLKNEKNQGISCIINDLTITIGTLFFCYTKYKNIYCNKVPIIEEKLTVKSMERHIYSCD
CNVHKTYQYLYSYSNSKKNESNNIIFMCIEGIVVGFFTLVDNIKPEVFELINFLKREKKKVYVC
TGDNYMNALYISKILGIKKENVSSNTLPLEKVQFVKKVQSMNDGKVCMIGDGINDCFALKTADL
Figure 7.0 PfCuP-ATPase sequence Continued
GLSLCTRTNVVMDSADACIVDNNINVIIKLFEISRKTLLVIKFNFLFSFFINIFFILLASGAFY
SLNYVFSPFLFTFLMFCSSIIVILSSLSLKLLLKNI

Figure 7.0 Protein sequence for PfCuP-ATPase. Colored
portions of the protein represent identified domains
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The two identified N-terminal metal binding domains of DdATP1, there is need to determine if
there exists inter-domain interaction, and whether Domain 1 can transfer copper to Domain 2. This
would shed more light as to why their metal binding motifs differ, and compare their metal binding
affinities. Furthermore, in this work, the copper binding affinity of the copper chaperone DdAtox1
was revealed to be higher than that of Domain 1. This may imply that the chaperone may be able
to donate the copper ion to this domain. Whether it can donate the metal ion to either of the
domains, has not been determined.
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